feel better live longer corporate responsibility report gsk corporate responsibility report approach report home search print back forward return last use navigation tools top right within report report available click icons move search print report section names take front section arrows content tables go underlined links go view additional information online report data data relate worldwide operations calendar year except stated data environment health safety sections report cr performance annually report supported references independently assured sgs information part commitment open information online www gskcom approach external assurance provided transparent business activities information corporate responsibility governance management section also included annual report brand names appearing italics throughout report year restructured report trademarks owned andor licensed gsk around four core themes reflect welcome feedback associated companies issues see important information report always reporting standards responsible sustainable business growth happy discuss questions may base report global reporting also reflect issues commonly may covered initiative gri guidelines produced gri raised stakeholders please contact us csrcontactgskcom index show elements guidelines covered report aid comparison company reports also joined un global compact provided index show reporting line global compact expectationsgsk corporate responsibility report approach contents contents approach people communities planet chairman introduction performance introduction waste ceo create value working gsk feature bringing carbon minimising use responsible business engaging employees science london supply chain materials source developing employees olympic operations environmental paralympic games stewardship diversity gsk propellants pulse environmental health safety employee volunteering feature understanding governance community impact investment products compliance water performance health water operations external assurance introduction developed countries research europe development usa behaviour improving access hivaids healthcare global viiv healthcare introduction clinical research challenge research development ethical conduct patient safety developing countries governance management increasing access preventing bribery supply chain increasing availability community investment corruption supply feature marketing products distribution process introduction stakeholder engagement approach malaria feature changing supplier standards approach performance improving affordability way incentivise performance value cr preventing disease sales teams usa security supply raising awareness publishing payments supplier diversity advocacy healthcare professionals public policy future plans publishing grants patient advocacy donations trade industry training awareness associations monitoring public policy activity compliance political contributions data privacy lobbying expenditure research practices patient advocacy animal research human rights gsk corporate responsibility report approach chairman gsk always believed year made good progress role chairman board corporate operating responsible responsibility committee acutely aware ethical way essential pressures challenges faced company receive regular reports addressed success business year particularly pleased see continued examine commitments made improve global access policies operations ensure medicines including agreements supply large quantities approach corporate vaccines protect rotavirus gastroenteritis pneumococcal diseases pneumonia responsibility supports delivery meningitis poorest countries world business strategy fractions western prices company also made substantive progress areas environmental consistent values sustainability supporting communities operate much progress due leadership sir andrew executive team board continue support constructively challenge thinking actions take operate responsible valuesbased business sir andrew witty left sir christopher gent right sir christopher gent chairmangsk corporate responsibility report approach ceo threeandahalf years ago set record demonstrates succeeding also demonstrated making significant increased sales returns shareholders progress improve returns productivity rd fundamentally change gsk significant progress research development seeing productivity translate real filings create different type company approvals three medicines approved remain committed operating transparency four ready file include delivering sustainable financial responsibility year made multiple new mek inhibitor melanoma new fourvalent advances agenda ensure behaviour performance providing shared flu vaccine actions meet even exceed expectations value patients consumers society much reflected report also cusp creating worlds first governments structured around four areas health people malaria vaccine seen firsthand devastating communities behaviour planet impact disease africa lived several years october latestage one key priorities continue align trials confirmed promise seen far showing commercial success forming new partnerships vaccine reduces risk malaria half tackle healthcare needs people developing african children aged months also reiterated countries particularly pertinent vaccines commitment price vaccine level covers tackling pneumococcal disease great example costs generates small return around partnerships make difference early ploughed back research next generation gsk began supplying pneumococcal vaccines kenya malaria medicines vaccines innovative financing mechanism known advance market commitment year also reached agreement principle largest fund ever designed single vaccine us government resolve longstanding dramatically increased sustainable access legal issues around sales marketing practices vaccine babies across africa settlement billion know difficult necessary step towards resolving multiple longstanding success built upon midyear announced matters reflect company today new pricing structure vaccine diarrhoeal disease offered gavi alliance vaccine fraction cost developed western markets millions children living worlds poorest countries set receive save countless lives future importantly offer sustainable long term recouping cost goods manufacture continued gsk corporate responsibility report approach ceo part ongoing strategy continue none would possible without efforts fundamentally change procedures compliance employees investing people communities marketing selling particularly usa underpins longterm sustainability business ensure operate high standards creating right internal external conditions integrity conduct business openly support strategy company mindful transparently continue innovate potential pressures employees face given current respond expectations stakeholders global political economic environment despite new compensation system rewards sales challenges remain committed offering representatives usa quality service rather employees range learning opportunities tailored sales volumes one example development volunteering programmes pulse programme example gives employees chance also made progress implementing join nonprofit nongovernmental organisation environmental strategy revised set three sixmonth placement pulse ambitious goals entire value chain raw volunteers delighted materials product disposal need work ways nearly employees countries served enable business growth protecting natural pulse volunteers since scheme began resources future example almost carbon footprint derives propellants patients changes others made right across use inhalers eliminating cfc gases business laying foundations future success products substantially reduced inhaler emissions come long way means million tonnes co equivalents less achieved everything aspire continue tonnes today review plans commitments across four areas looking establish longterm goals sir andrew witty hears patients visiting hospital uganda targets support meaningful measurement demonstrate commitment responsible valuesbased business continue restless challenge ask sir andrew witty chief executive officergsk corporate responsibility report approach scienceled global healthcare gsk three primary areas business pharmaceuticals turnover region vaccines consumer healthcare company make innovative bn products used millions pharmaceuticals business develops makes usa available medicines treat range serious infectious europe people around world chronic diseases portfolio made emerging markets asia pacific established brands newer innovative patent products develop japan manufacture way protected medicines total vaccines business one largest world contributes directly producing paediatric adult vaccines range health wellbeing patients infectious diseases many products use components single vaccine help provide employees region consumers indirectly protection multiple diseases society economy consumer healthcare business market usa europe range categoryleading consumer health products e merging markets areas oral health nutrition wellness asia pacific skin health japan business sustained investment rd total spent billion search develop new medicines vaccines innovative consumer products annual report read business strategy performance well find f lie el b loe ntt ge er r detail corporate governance risk management annual report shareholders annual report onlinegsk corporate responsibility report approach create value place great importance innovation employees positive impact contribution makes peoples lives one key motivators achieve also new medicines healthcare products needed working gsk achieve believe business people across globe address many illnesses still wellcontrolled treated time diverse balanced portfolio across play greater role scientific research continuously uncovering new pharmaceuticals vaccines consumer healthcare products provides us range products tackling social economic understandings disease processes technologies grow business changes made environmental challenges two elements present us opportunity shape business intended provide broadly investigate develop new improved treatments sourced sales growth greater resilience face create value applying science technology market challenges discover develop produce distribute medicines developing new partnerships approaches vaccines consumer healthcare products adopting mindset innovative openminded access flexible value new different perspectives working research charities academia companies actively seeking new ways delivering healthcare nongovernmental organisations among others making products available affordable flexible intellectual property people need wherever live knowhow stimulating progress search society expects us right thing new treatments also good business also increasing consultation patients effort expand access products payers ensure develop medicines healthcare led industry adopting flexible approach pricing systems value reward medicines vaccines based countrys wealth ability pay resulted significant approach responsible business reductions price increases demand responsible business grow create products emerging economies representing good value shareholders society strategy outcome patients governments shareholders designed maximise performance committed western markets developed new reimbursement operating responsibility transparency strong approaches medicines agree risksharing values people central business success arrangements payers report outlined progress around four different themes reflect issues see important responsible sustainable business growth fundamentally changed business culture help us grow innovate improve reviewing plans commitments across performance affects way business way four areas plan establish targets key work others relationship employees performance indicatorsgsk corporate responsibility report approach responsible business health people communities investment rd infrastructure respect people support employees innovative pricing working stakeholders reach full potential make positive difference make medicines vaccines consumer products communities operate available many people need possible economic contribution investment education regardless live ability pay programmes partnerships planet behaviour committed minimising environmental building strong valuesbased culture impact across value chain lifecycle recognise need open products setting ambitious goals reduce carbon challenges face actions footprint water waste backed robust policies strong compliance processes expect standards suppliers contractors business partnersgsk corporate responsibility report health contents introduction developed countries research europe development usa improving peoples health improving access hivaids healthcare global viiv healthcare wellbeing regardless challenge research development developing countries live ability pay increasing access increasing availability community investment feature approach malaria improving affordability preventing disease raising awareness advocacy future plans click arrows go section improving access healthcare one societys pressing social challengesgsk corporate responsibility report health introduction want make products progress available accessible affordable invested billion global rd cofounded made significant delivered vaccines many people need launched three new commitments intellectual use developing countries possible aim medicines expect report property wipo research new million doses latestage assets end coalition stimulate research kenya ethiopia become first generating returns need diseases developing world countries africa introduce sustain business invest first results ongoing phase iii gsks pneumococcal vaccine research studies malaria vaccine began six rd projects open synflorix innovative candidate rtss showed able lab tres cantos diseases financing mechanism reduce risk malaria half developing world seven new commitment supply understand recognise many barriers african children aged months approved million doses gsks anti obstacles path better health oneyear period invested million diarrhoeal vaccine rotarix committed finding new innovative ways vaccination partnerships amref care reduction western market price tackling working partnerships listening new commitment support international save children others prepared change way business creating value society business research efforts usa europe support training frontline us patient assistance programs shareholders tackle antimicrobial resistance healthcare workers least provided gsk medicines developed countries vaccines worth million outline global approach contribution helped create new coalition led expanded work valued cost going detail work developing world health organization healthstore foundation improve viiv healthcares licensees supplied countries challenge increasing access control eliminate healthcare rural slum areas million tablets healthcare particularly difficult however access neglected tropical rwanda kenya establishing versions epivir combivir issue developing world also diseases network nurse runclinics setting lowincome least developed include examples work developed countries extended albendazole donations new target health posts countries subsaharan africa enable deworming schoolage staggered sevenyear period children endemic countries gsk corporate responsibility report health research development important contribution launched three new medicines benlysta well significant partnerships address neglected treatment systemic lupus erythematosus horizant tropical diseases ntds main areas collaboration make improving health treatment moderatetosevere restless legs include research improving drug discovery research development new syndrome trobalt adjunctive treatment partial biotechnology identifying patient safety issues onset seizures start critical twoyear research rare diseases signed seven new treatments vaccines consumer period pipeline expect deliver phase iii collaborations giving us external healthcare products data readouts assets end discovery partnerships complement internal discovery units date positive readouts supporting progression focus rd products contribute society towards registration several assets diseases including also fund basic medical research conducted outside addressing patient needs advances science type diabetes chronic obstructive pulmonary disease gsk increase understanding human body offer best opportunities discover new medicines copd asthma hepatitis c melanoma malaria impact disease type research frequently generate commercial returns foundation future advances diagnosis discovery performance units dpus helping successful long term need treatment prevention disease us improve productivity rd small investments making pipeline lead new entrepreneurial multidisciplinary teams responsible focus finding best science wherever may medicines valued patients discovering developing potential new medicines led creation discovery partnerships pay treatments medicines vision process specialist areas develop threeyear business academia dpac programme dpac new approach ensures voice customer integrated plan make pitch funding projects aims establish truly integrated partnerships medicine development strategy optimise payer front discovery investment board dib academic groups undertake early drug discovery patient prescriber needs completed majority threeyear progress reviews translate innovative research medicines invested billion rd dpus decisions made benefit patients expenditure pharmaceutical rd number shape projects continue dpac engaged nearly academic institutes remainder vaccine consumer healthcare research proposals new dpus countries around world four new areas emerged pipeline around assets latestage vaccines business collaborations external way working future remain flexible development around candidate vaccines partners ongoing prophylactic landscape changes development approximately onethird target therapeutic vaccines diseases particularly prevalent developing right across rd organisation form alliances read rd dpus medicines world read pipeline progress external groups accelerate discovery new vaccines pipeline progress approvals annual report medicines vaccines well share scientific annual report website understanding ultimately improve patient caregsk corporate responsibility report health case studies research development focus patient tackling antimicrobial resistance guide research essential us understand antibiotics cornerstone modern medicine barda group within office assistant patients need focus patient programme effectively treating common infections secretary preparedness response us brings patients gsk sites speak directly rd ensuring patients undergoing surgery department health human services also teams healthcare needs helps us make immunocompromised example chemotherapy supported introduction generating antibiotics better medicines inspires employees hiv transplantation protected infection incentives gain act house help improve patients lives gsk leading researcher supplier representatives june believe could effective antibiotics many years antibiotic meaningful step towards addressing barriers hosted patient insight seminars sites augmentin remains use around world today research development approval new antibiotics theme strengthening patient voice years since first launched gsk brought together people november gsk welcomed european including gsk employees healthcare professionals however past years seen increasing commissions action plan rising threats patients patient advocacy group representatives resistance infectious bacteria antibiotics antimicrobial resistance promotes discuss range topics including epilepsy ovarian time decline antibiotic research two new collaborative research develop new antibiotics cancer asthma immune thrombocytopenia diversity classes antibiotics developed launched counter growing threat resistant bacteria us clinical trials acute lung injury plasmodium vivax last years european centre disease share european commissions view public malaria fabry disease crohns disease soft tissue prevention estimated europe people die private collaboration sharing information sarcoma copd provide recordings resistant infections five types bacteria funding offers best way forward seminars dedicated area intranet enabling committed working innovative medicines employees learn benefit discussions discovery development new antibiotics initiative imi antibiotics programme takes many years significant investment yet new teams across gsk looking research partners antibiotics licensed generally used area patients failed respond existing treatments limiting commercial return needed encourage believe approaches also needed continued research investment support innovation area example investment research new antibiotic products would gsk one pharmaceutical companies otherwise commercially viable could encouraged active antibiotic rd programme committed guaranteeing financial agreement success supporting efforts tackle antimicrobial resistance believe regulatory approaches reflecting september gsk biomedical advanced unique challenges developing treatments multi research development authority barda drug resistant infections urgently needed usa agreed million contract support development gsk potential new antibiotic hospital gram negative biothreat pathogens european centre disease prevention european medicines agency joint technical report bacterial challenge time react gsk corporate responsibility report health improving access healthcare global challenge improving access healthcare many complex factors hamper access believe right thing know medicines developing countries poverty single approach contribute business success one societys pressing biggest barrier many countries people striving meet societys healthcare needs also social challenges enough food clean water access functioning build trust business helps safeguard health system medicines prevalent diseases may licence operate long term lacking limited commercial return rd every year millions people die curable improving access healthcare emerging economies neglected diseases often unified registration preventable infectious diseases suffer unnecessary ill also helps us build business increasingly system medicines makes process costly health access basic healthcare commercially important markets brazil china complex individual authorities sufficient services including essential medicines vaccines india indonesia russia past majority capacity numerous product registrations cost healthcare barrier access patients revenue countries came selling developed developing world despite many developing countries distribution network medicines vaccines higherincome sectors huge medical advances still many conditions medicines weak lack basic infrastructure society achieve sustainable growth need go treatments exist need improved hospitals clinics healthcare professionals barriers beyond highincome sector increase access often compounded lack political action affordability patients lowerincome levels problems affect individuals communities resulting inadequate funding across healthcare countries means ensuring right around world acute developing system middleincome countries health system may products right prices right places countries particularly worlds least developed developed differences income levels countries ldcs wherever possible work partnership companies prevent access problems must excuse governments international agencies academic institutions access medicine index inaction indicate action needed patient groups ngos communities providing gsk ranked top access medicine atm want help improve health business expertise resources medicines vaccines improve index published second time index activities skills resources acting catalyst healthcare infrastructure availability produced atm foundation provides wider change across industry society strategy medicines vaccines working together independent assessment company efforts focuses make difference achieve patients alone improve access medicines particular improving affordability availability prevention approach reflects different needs market supporting vulnerable health systems also pleased progress recognised vary significantly depending poverty focused conducting encouraging investment know still done income levels coverage quality healthcare rd achieve continue consider recommendations infrastructure political commitment resources atm index carefully reviewing approach working open manner better reflecting allocated healthcare however common publication next atm index expected later needs developing countries themes address across regions pursuing flexible pricing strategies working innovative partnerships try reach people would otherwise access medicines vaccinesgsk corporate responsibility report health improving access healthcare global challenge increasing availability addition research improving affordability pricing one factor preventing disease work tackle development innovative products focus impacts access medicines vaccines root causes disease illhealth contribute tackling diseases particularly prevalent developing adopting range innovative pricing models reflect healthier communities around world example countries including neglected tropical diseases also commitment work governments vaccines play major role preventing disease work improve availability medicines increasing stakeholders deliver medicines vaccines acknowledged among product registration across many markets includes many people need possible also costeffective health investments estimated new products making sure existing products seeking methods improve affordability least three million deaths prevented widely available broadening portfolio innovative financing mechanisms smaller pack sizes children saved disability due vaccines make relevant health needs people every year vaccines approved flexible pricing help build business developing countries marketing address medical needs developing emerging markets increasing overall volume developed countries cover leading strategic alliances acquisitions help us grow products sell however ability offer notfor causes childhood mortality business developing countries bring bigger profit highly preferential prices worlds poorest range affordable medicines wider population countries sustainable continue make also work partnership others improve currently supply medicines vaccines directly adequate return medicines vaccines health example partnership eliminate majority ldcs looking opportunities betteroff markets challenging lymphatic filariasis phase handwashing expand presence countries africa uncertain economic climate governments seek campaign read partnership ngos un organisations example contain healthcare costs recognise challenge recently relaunched gsk angola zimbabwe working governments europe usa established initial distribution route somalia find solutions seek price medicines fairly operating fragile states challenging important countries level reflects value patients order bring medicines need payers read approach invest profits business ldcs back projects strengthen healthcare infrastructure countries support innovative africa shoulders global disease burden approaches healthstore foundation one global health workforce family health child family wellness nurse run franchise health posts read work global health budget partners ehreth j global value vaccination vaccine world health organization world health report working together healthgsk corporate responsibility report health developing countries challenge increasing access increasing availability oversight management healthcare particularly difficult improving access healthcare core gsks overall developing world rd worlds least developed countries strategy prioritised highest levels urgent need newer better medicines company ceo sir andrew witty closely involved vaccines use developing countries ldcs often disease burden often spoken publicly commitments greatest resources tackle views set article global health issues committed finding innovative ways help published leading us journal health affairs address gap integrating research developing lacking world pharmaceutical vaccine rd president gsks emerging markets asia pacific organisations stimulating rd beyond gsks region abbas hussain leads access efforts developing countries population million significant investment countries reviewed corporate executive half live less day team corporate responsibility committee within emerging markets asia pacific business challenges include weak infrastructure supply chains board unit covers developing countries support provision medicines vaccines small specialised rd unit dedicated developing drugs overstretched health workforces low population literacy developing countries market access dcma patients countries championing needs levels food insecurity many middleincome countries operating unit set specifically increase patient throughout rd operations focuses late stage mics brazil china india indonesia thailand access gsk medicines vaccines expanding clinical products match needs patients also large numbers people living extreme poverty presence building sustainable business country developing countries areas unit working include healthcare demands often outstrip available resources managers gsks businesses ldcs report unit adapting gsk products better meet needs challenges made worse increasing incidence enabling tailored consistent integrated approach patients developing countries noncommunicable diseases asthma diabetes increasing access countries reflecting specific needs unit also working gsk country managers creating better evidence based formulations ebfs improving access healthcare developing countries developing countries increase access fixeddose combinations generic medicines offer requires holistic approach embracing prevention flexible pricing approaches dcma unit aims improved clinical outcomes lower price consistent treatment efforts fundamentally strengthen health increase availability gsk medicines broadening latest evidence scientific literature systems stakeholders need contribute portfolio make relevant people treatment guidelines committed playing part countries pricing increase access unlock partnering research institutes governments investing developing countries including ldcs demand contributing education awareness innovative research understanding longterm help ensure sustainable successful business expanding distribution supply chain capability healthcare priorities mix funding technology regions grow countries develop transfer talent development recently established future strategy groups use term developing countries include fsgs review approach key business issues investigating new ways reach patients including least developed countries identified un address strategic challenges led smaller pack sizes mobile phones currently countries including south sudan ceos office bring together senior managers countries subsaharan africa lowincome experts around business fsgs focused middleincome countries defined world bank topics neglected tropical diseases ntds hugely diverse group approach reflects access medicinesgsk corporate responsibility report health developing countries increasing availability also rd group focused specifically highlights ddw rd portfolio diseases developing world ddw including ntds prioritises research decisions socio rd portfolio includes projects number diseases particular relevance developing countries including bacterial economic public health benefits rather meningitis chagas disease chlamydia dengue fever hivaids human african trypanosomiasis leishmaniasis malaria pandemic commercial returns significant portion drug flu pneumococcal disease tuberculosis tb gsk one companies researching new vaccines treatments discovery work takes place dedicated facility tres three world health organizations priority infectious diseases hivaids malaria tb cantos spain similar group active vaccines highlights pipeline developing world illustrated organisation belgium hivaids viiv healthcare industryleading pipeline six potential antiretroviral medicines including five entered several new research partnerships focusing compounds phase ii phase iii development altogether compounds investigation ddw include development potential new hiv treatments read viiv healthcares progress phase iii development programme commitment research two collaborations related research kinetoplastids development support populations hardest hit epidemic parasites responsible serious diseases also involved aids vaccine research two decades pursuing four separate collaborations providing access vaccine strategies successful aids vaccine might combine several approaches proprietary compound library gsks hiv vaccine candidate fas currently phase clinical trials hivinfected subjects evaluate collaboration build early stage drug discovery safety efficacy efforts tuberculosis tb fas vaccine candidate also combined recombinant adenovirus vector collaboration international aids vaccine initiative iavi continue play active role commitment gsk working pasteur institute paris partners develop aids vaccine fusing support rd efforts developing new better genes hiv virus onto measles vaccine vector phase clinical trial started treatments ntds collaborative partnerships collaborative discovery rd programme aims identify hiv envelopebased protein vaccine capable drugs neglected diseases initiative producing broadly neutralising antibodies hiv infection conducted multiple partners dndi notforprofit rd organisation share knowledge research intellectual property groups malaria read progress malaria vaccine candidate dndi support drug discovery efforts also developing tafenoquine potential treatment radical cure plasmodium vivax malaria diseases including sleeping sickness visceral leishmaniasis frequent widely distributed cause relapsing malaria affects millions people year mainly south east asia latin america tafenoquine developed partnership medicines chagas gsk founder member wipo malaria venture mmv entered phase iiiii study initial study understand tafenoquine research consortium gpd deficiency common gene deficiency areas malaria prevalent affect choice malaria treatment began interim results expected tuberculosis tb worlds second leading cause death infectious disease working aeras global tb vaccine foundation tuberculosis vaccine initiative developing tb vaccine candidate date conducted phase ii trials tbnave tbinfected bcgvaccinated adults well hiv positive adults taking combination antiretrovirals phase ii trial african infants ongoing dengue fever joint rd initiative fiocruz walter reed army institute research develop vaccine dengue fever continued scientists gsk fiocruz working across facilities brazil belgium partnership also enhance brazilian rd capacitygsk corporate responsibility report health feature approach malaria past decade seen significant progress fight malaria leading commentators believe world zero deaths disease becoming possible progress certainly encouraging global deaths reduced almost many african countries implementing extensive control programmes limit transmission yet despite recent successes half worlds population remains risk malaria still kills almost people every year children age five subsaharan africagsk corporate responsibility report health feature approach malaria approach trial one final stages evaluating vaccine partnership candidate infants young children regulatory believe comprehensive approach malaria single organisation ability defeat malaria file submission conducted centres seven required scale use established tools inroads made countries across subsaharan africa control continuing invest development formation innovative partnerships rtss use innovative new tools widespread results needed developed partnership mvi received introduction impregnated bed nets complemented million grants bill results weekold infants expected use effective antimalarial medicines melinda gates foundation advance clinical end required public health information turn complement methods indoor residual development rtss together prominent african including safety efficacy data phase iii spraying insecticides successful vaccine could research centres programme deemed satisfactory world health next weapon armoury organization indicated policy recommendation collaboration medicines malaria venture pivotal year rtss malaria vaccine candidate possible mmv also developing tafenoquine potential early potentially paving way decisions treatment radical cure plasmodium vivax believe vaccines simplest cost african nations introduction vaccine malaria frequent widely distributed cause effective way save lives landmark national infant immunisation programmes recurring malaria affects millions people gsks near year search malaria vaccine october year mainly south east asia latin america first results ongoing largescale trial pricing see published new england journal medicine pledged pricing barrier revealed malaria vaccine candidate rtss existing tools could benefit malaria vaccine potential reduce risk malaria half african approved recommended use eventual price also working partnership children aged months one year period rtss set cover cost producing organisations increase availability uptake vaccination developing rtss partnership vaccine together small return around preventative measures improve management path malaria vaccine initiative mvi reinvested research development malaria particularly young children subject evaluation safety quality secondgeneration malaria vaccines research pregnant women efficacy vaccine candidate well benefits neglected tropical diseases since committed million risks regulatory public health authorities invested million vaccine far african malaria partnership amp data bring us cusp worlds first malaria expect invest another million next encourage behavioural change sleeping vaccine potential significantly improve years expect recoup costs insecticidetreated bed nets seeking treatment outlook children living malaria endemic regions sales vaccine little market early stages disease across africa addition malaria vaccine existing vaccine developed countries ability make control interventions could potentially help prevent communities tanzania ghana nigeria kenya significant investment returns innovative millions cases could also reduce burden currently working partners national medicines portfolio enables us support hospital services freeing muchneeded beds treat malaria control programmes help build capacity important work also donate least million patients often live remote villages little community health workers mobilise families doses vaccine mvi access healthcare become frontline fight malariagsk corporate responsibility report health developing countries increasing availability open innovation open lab builds partnership approach contributing patents patent applications always taken tres cantos since site established wipo research covering small molecules formulations need think differently conduct worked closely publicprivate directed developing treatments delivery technologies rd find new ways work key stakeholders partnerships groups medicines malaria ntds well compounds partnership essential pursuing venture global alliance tb drug development screening shown evidence activity malaria open innovation approach working industry scientists working centre academia ngos governments includes since wipo research incorporate point data many posts funded partners sharing expertise resources scientists information expect point likely discontinue around world tres cantos open lab sharing intellectual property following transition period sharing intellectual property knowhow research gsk committed sharing intellectual property sharing research information data help stimulate research outside gsk knowledge may help speed research ntds published research findings could open data ddw research helped establish pool open help identify potential new treatments malaria help stimulate research outside gsk innovation neglected tropical diseases point research result yearlong screening tres cantos open lab contributed patents patent applications process five gsk scientists reviewed also committed consider requests access two million compounds gsks chemical library seek open laboratory tres cantos site spain knowledge experience terms point could inhibit malaria parasite space visiting scientists universities notforprofit medicines treatments ntds developed using process identified compounds showed partnerships research institutes pooled patents intellectual property available greatest activity molecules barcelona centre international health research least developed countries royaltyfree basis one proprietary gsk first time cresib weill cornell medical college usa current projects underway tres cantos open made available wider research community imperial college london work projects lab result information shared via point developing world learn expertise share shared compound set various groups worldclass facilities gsk also founding member wipo research researchers encourage share new collaboration among private public sector results become available aim identify six projects began open lab organisations designed accelerate ntd research datasets make publicly available act seven approved begin ten projects launched new platform provides searchable catalyst stimulate research ddw supported tres cantos open lab foundation public database available compounds resources charity established million funding gsk expertise knowledge used researchers projects supported partners bill treatments developed intellectual property melinda gates foundation wipo research website must made available governing board leading scientists providing royaltyfree least developed countries strategic direction foundation projects must contribute research helps discover new medicines diseases developing worldgsk corporate responsibility report health developing countries increasing availability strengthening healthcare infrastructure highquality affordable essential medicines places supporting vaccination training counterfeit substandard drugs common chronic shortage trained frontline health workers since supported work network ldcs recognised one fundamental cfw franchisees receive support healthstore education support immunisation nesi constraints achieving millennium development form startup loans initial training coaching system promote vaccinology training healthcare workers goals world health organization estimates wide marketing support peer network recognition subsaharan africa north africa middle east shortfall least one million frontline health workers technology innovations nesi become key partner organisations particularly africa parts asia gsk supporting expansion via grant unicef gavi implement increasing number frontline health workers implement cfw clinics rwanda second phase vaccination programmes regions also immediate costeffective way save lives planned ultimate goal establishing continue support global public health training improve health outcomes especially mothers clinics troped network troped encompasses children example settings fully trained approximately european universities wellsupported community health worker institutional partners across globe effectively deliver treatments provide health education children year using mobile phones tackle counterfeiting nigeria committed becoming partner finding solutions healthcare delivery ldcs counterfeit medicines illegal gsk piloting innovative approach service looks code reinvesting profits made countries often dangerous problem protecting patients africa sends verification text back local healthcare infrastructure supporting global acute counterfeit medicines using mobile consumer also tollfree efforts expand access frontline healthcare workers developing world regulation phones taking advantage high phone number consumers call law enforcement capacity mobile phone penetration rate questions supporting frontline health workers coalition relatively weak counterfeit africa average fhwc new coalition companies ngos urging response consumers medicines account around greater strategic investment frontline health february began using text enthusiastic received products sold africa workers developing world costeffective messaging part sixmonth pilot texts unique users way save lives mothers children address anticounterfeiting programme representing approximately use aids global health threats nigeria antibiotic ampiclox ninety per cent texts returned pilot run collaboration genuine confirmation received also working healthstore foundation nigerias national agency counterfeit alert others received transitioning one family health private enterprise food drug administration message indicating duplicate pin developed child family wellness cfw control nafdac place calls made franchise system enables local nurses scratchoff code back helpdesk helps us operate basic medical clinic rural slum areas ampiclox antibiotic pack consumers identify counterfeit ampiclox blisters africa cfw clinics target diseases conditions send code via text message nigerian market intend cause around illness death local central nafdac tollfree phone roll approach products communities including malaria diarrhoeal disease number verification mobile well countries east africa respiratory infections maintain secure supplygsk corporate responsibility report health case study developing countries increasing availability reinvesting profits ldcs worlds ldcs lack basic healthcare infrastructure lack access quality health facilities services affects supporting innovative elearning project qualified healthcare workers prevents millions people many poor women newborn infants farwestern tanzania upskill nurses remote regions getting treatment need gsk reinvest region nepal gsk supporting initiative led betterinformed healthcare advances profits make pharmaceutical care international upgrade local community health best practices able provide higher standard consumer healthcare businesses ldcs back local service centres birthing centres improved facilities care rural communities working closely healthcare infrastructure partner three leading provide training mobilise female education institutions ministry health ngos amref care international save children community health volunteers amref develop distance learning courses specifically address shortage trained frontline healthcare workers funding available investment million based profits medicines consumer healthcare products afghanistan enabled us initiate programmes train health workers initiated projects nepal countries end track implement project profitmaking ldc bangladesh june mauritania mali niger myanmarlaos chad goals include senegal yemen bu fr ak si ona sudan djibouti cambodia measuring impact projects including guinea sierra leone central ethiopia n inu hm eb ae ltr h n h de ia cl th rw sorkers trained improvement liberia tog bo enin ra ef pr uic ba lin c uganda engaging organisations help achieve democratic republic rwanda goal one million health workers developing congo burundi countries tanzania examples activities investment angola zambia supported outlined mozambique madagascar niger one six children dies five haiti help prevent working save children initiatives maradi region conduct health education sessions initiatives lesotho communities training community initiatives health volunteers deliver health nutrition messages acknowledge sudan split north south sessions focus causes malnutrition running programmes country ways preventing common childhood diseases ldcs made profit programme implemented midgsk corporate responsibility report health developing countries improving affordability improving affordability focus noncommunicable diseases innovative pricing noncommunicable diseases ncds becoming ncds ncds represent disease burden ldcs cap prices patented medicine prevalent developing countries improvements developing countries measured disability vaccines prices uk tackling childhood infectious diseases lead adjusted life years dalys accepted measure reflect unique situation hivaids viiv people living longer changes lifestyles disease burden one daly equivalent one healthcare offer notforprofit prices hivaids cardiovascular disease cancer diabetes chronic lost year healthy life see chart medicines ldcs subsaharan africa respiratory diseases already account deaths lowincome countries see offer tiered countries rich poor prevalence global burden disease pricing gsk vaccines worldwide growing fastest middle lowincome countries increasing access medicines ncds dalys million introduced similar price reductions particularly challenging cost providing high income countries nonldcs reduce risk product diversion longterm even lifelong care gsk committed want reduce likelihood notforprofit finding innovative solutions challenge preferentially priced medicines illegally shipped middle income countries back sale betteroff countries undermines september un general assembly hosted purpose reducing prices improve high level meeting new york devoted ncds low income countries access poor countries gsk participated meeting worked members ifpma international federation low middle income countries middleincome countries implementing range pharmaceutical manufacturers associations approaches balance commercial objectives publish framework action industry need increase access medicines patients focused areas prevention innovation access markets afford pay include communicable diseases capacity building partnership key output noncommunicable diseases flexible pricing models tailored products local meeting political declaration prevention sourcing manufacturing arrangements control ncds provides mandate also exploring opportunities make medicines un member states make ncds priority available smaller pack sizes make declaration also calls focus prevention affordable patients pay prescriptions fosters multistakeholder approach already include ncds many pricing access initiatives looking new ways improve access within sustainable business models examples include work develop lowcost asthma products global status report noncommunicable diseases specifically patients developing world see ifpma framework increased focus ncds may provide political declaration prevention control ncds opportunities work governments global burden disease report updated nontraditional ways try expand access disabilityadjusted life yearsgsk corporate responsibility report health developing countries improving affordability pricing caps least developed countries ldcs sales volumes majority products increased pricing vaccines significantly following price decreases believe since reduced prices ldcs years made entire vaccine increased access products patients gskpatented products individual product lines portfolio available expanded immunisation formulations sole supplier also reduced prices offpatent programmes preferential prices developing market prices capped antibiotics augmentin zinnat certain countries using tiered pricing system price uk france products sold countries seen increase sales volumes prices linked gross national incomes defined uk provided price covers manufacturing costs example decreased price zinnat world bank well size order offer sustainable prices reduced average bangladesh volumes increased yearon length particular supply contract selling apply following brands year across product range vaccines large volumes longer term contracts seretide asthma chronic obstructive pulmonary vaccines sold small private market ldcs able significantly reduce price disease copd also offered western european average individual dose gavieligible countries prices avamys rhinitis gavi alliance unicef purchase large little tenth developed countries flixotide asthma volumes vaccines worlds poorest children model works vaccines demand relatively always benefit gsks lowest prices predictable due nature vaccination prevention malarone malaria compared use medicines treatment avodart benign prostatic hypertrophy measure impact price reductions also introducing flexible pricing vaccines sold directly increases sales volumes also received fraxiparine anticoagulant governments customers anecdotal feedback physicians indicating ultiva anaesthetic patients using medicines patient extended advance market commitment arixtra venousthromboembolism vte compliance prescribed dose improved amc agreement gavi alliance speed access zeffix hepatitis b cases pneumococcal vaccine synflorix supply million doses synflorix gavieligible countries cases price countries priced around reductions passed patients worked cost developed markets respiratory governments media pharmacists others pneumococcal disease leading cause death pharmaceutical distribution network children five developing countries vaccine medicines transparency alliance make sure patients could help protect million children aware benefit reductions next decade synflorix introduced kenya beginning see sales volumes increasing countries cap ethiopia far launches expected amc designed accelerate access vaccines bystimulating rd manufacture vaccines affordable prices longterm agreements price patented average price reduction manufacturers synflorix introduced africa months introduction europe medicines vaccines brands ldcs compared uk pricesgsk corporate responsibility report health developing countries improving affordability rotavirus infection one leading causes middleincome countries flexible pricing believe approach impact childhood mortality developing countries gsk examples innovative pricing approach many middleincome countries mics brazil supplying rotavirus vaccine rotarix gavi outlined china india indonesia thailand growing markets alliance per dose small fraction developed gsk represent important source future avamys oncedaily nasal spray treating allergic world prices committed supply million business strategy grow business mics rhinitis reduced price avamys doses rotarix next five years enable making products affordable lower average mics volumes avamys sold gavi meet aim expand rotavirus vaccination income levels turn increases volume increased fourfold since introduced flexible pricing countries sudan became first products sell introducing flexible increase number packs sold country africa introduce rotarix support pricing approaches take account differences offset impact lowering prices gavi alliance economic status demography healthcare infrastructure enabled us reduce cost goods together synflorix rotarix agreements gavi pricing regulations patient affordability introduced tiered pricing oncology products contribute potential immunise million flexible pricing approach includes tykerb breast cancer treatment emap children make substantial contribution improving affordability linking pricing policy markets example india reduced price achieving millennium development goal reducing closely countrys gross national income gni tykerb july seen growth child mortality twothirds volumes previous year data introducing differential pricing within markets reach suggest patient adherence tykerb treatment also supply portfolio vaccines affordable prices new sectors population based assessing patient improved least pan american health organization paho ability pay purchases behalf middleincome developing working closely health authorities payers brazil decreased price antibiotic countries latin america caribbean agree innovative pricing programmes medicines treatment augmentin volumes arrangements help protect estimated support disease awareness campaigns increased yearonyear across range million infants rotavirus rotarix estimated closely monitoring prices compared local million babies pneumococcal infections competition regularly reviewing synflorix girls cervical cancer cervarix developed guidance flexible pricing new products launched emerging markets asia pacific emap region market access pricing team works local operating companies establish right pricing approach market helps share information best practices market access children potentially amc synflorix immunised priced cost gavi agreements developed markets synflorix rotarixgsk corporate responsibility report health developing countries improving affordability innovative financing models medical insurers cover cost treatment local manufacturing strategic alliances patients respond beyond week gsk refunds innovative financing break barriers access achieving higher sales volumes help reduce costs cost treatment patients whose disease improving affordability patients example goods pass price reductions progressed week initiative demonstrates treatment postmenopausal women risk bone ultimately increasing access products addition belief products efficacy ability deliver fracture due osteoporosis prolia denosumab commercial teams collaborate manufacturing equivalent benefits iv treatments lower cost administered via injection every six months organisation explore local sourcing manufacturing way convenient patient piloting new patient access schemes pas argentina licensing arrangements brazil chile philippines singapore ukraine introduced discount cards ukraine argentina vaccines business number joint pas benefit patients pay part chile vietnam help groups patients ventures technology transfer arrangements prescription costs market adopted senior citizens disabled people lowincome patients help increase supply affordability vaccines approach best suited needs example argentina chronic diseases may able afford enabling developing countries develop launched programme allows patients pay copayment element prescription medicines research manufacturing capabilities increasing prolia six interest free instalments reducing initial also partner others example morocco market access gsk read approach expense making prolia accessible patients working lalla salma association cancer technology transfer position paper online option makes prolia accessible ngo provide oncology medicines tykerb population increase arrangements include agreement zofran significantly reduced price means binnopharm russia covering vaccines human also introducing risksharing models number patients limited means insurance estimated papillomavirus hpv rotavirus streptococcus markets help speed patient access around population treated public longstanding partnership brazils oswaldo cruz treatment may need demonstrate value hospitals charge foundation covering polio haemophilus influenzae products help governments manage type b hib measles mumps rubella rotavirus spending example brazil launched pneumococcal disease china initial joint performancebased financial risksharing scheme venture shenzhen neptunus newly breast cancer treatment tykerb also known tyverb whollyowned subsidiary develop manufacture giving access eight million extra patients influenza vaccines brazilian governments policy reimburse oral oncology treatments tykerb physicians therefore tend prescribe intravenous iv treatments invasive mean patients spend time hospital new scheme tykerb prescribed patients assessed weeks treatmentgsk corporate responsibility report health developing countries preventing disease raising awareness preventing disease raising awareness respiratory disease developing world raising awareness fundamental aspect good health management clear medical need developing world ensure people well informed avoid make major contribution preventing disease getting ill look fall ill people education awareness chronic respiratory illhealth significant contribution adequately informed take right conditions particular asthma assess current vaccines business many products precautions seek appropriate treatment reach respiratory business fully understand including hivaids viiv healthcare necessary malaria good example barriers access analysed asthma control diabetes prevent diseases progressing severe significant effort invested encourage people perception towards asthma access healthcare forms consumer products help prevent tooth sleep insecticide treated bed nets look various developing countries revealed high decay help people stop smoking improve nutrition early signs malaria efforts contributed levels poor asthma control inadequate treatment phase community investment programme significantly recent declines mortality frequent hospitalisations asthma attacks stigma contribution global alliance eliminate lymphatic malaria see suggests better training among healthcare filariasis also outlined professionals public awareness campaigns pharmaceutical business flexible pricing programmes targeted addressing affordability vaccines approach often accompanied comprehensive access issues would improve respiratory problems gsk vaccines included immunisation campaigns campaigns increase awareness turn make sure markets countries worldwide billion vaccine maximum number patients benefit responded number approaches doses delivered million doses price reductions increased access one example including rolling programme regional shipped use developing countries indonesia reduced price across respiratory masterclass awareness education include least developed low middleincome number established brands sessions key regions also reviewing countries gsk leading vaccine supplier setting prices realistic level reflecting countrys supply chain cost reduction opportunities exploring organisations unicef pan american ability pay disease education media awareness innovative packs presentations approaches health organization paho campaign supported gsk launch event may support access including filling gaps physicians held attended minister september agreed donate million worth current product portfolio health efforts well expansion cervical cancer vaccine cervarix usbased pink healthcare professional coverage addition came longterm agreement ribbon red ribbon partnership covering countries helped increase access supply ventolin inhalers global asthma drug girls women africa access vaccination medicines example volume seretide facility adf adf procurement programme next five years gsk also pledged asthma treatment almost doubled following aims make essential asthma medicines available support pink ribbon red ribbons programme operations approximately price reduction affordable low middleincome countries helping expand availability vital prevention screening treatment programmes cervical breast furthermore working raise awareness cancer developing countries partnership also disease improve prevention treatment focusing integrating lowcost screening treatment developing countries example phase services aims reduce deaths cervical cancer handwashing programme participating areas africa next five yearsgsk corporate responsibility report health case study developing countries preventing disease raising awareness approach neglected tropical diseases ntds one billion people afflicted expanding donation albendazole elimination programme first one ntds listed eight years conservatively estimated expanded albendazole donation world health organization billion programme targets two ntds diseases mainly affect people lymphatic filariasis lf soil intestinal worm infections stunt marginalised poverty live transmitted helminths sth intestinal growth cause anaemia remote rural areas urban slums worms pledged extend malnutrition impact childs conflict zones limited access additional five years commitment ability learn affect performance effective healthcare clean water donate million albendazole school scaling donation sanitation adequate nutrition proper treatments year help achieve target housing transportation education enable deworming schoolage children reaching school children impact ntds prevents personal endemic countries globally live countries community national economic intestinal worms endemic development perpetuates poverty established commitment donate albendazole long started ship tablets january joined global necessary lf also known schoolbased deworming ahead schedule pharmaceutical companies leading elephantiasis eliminated currently togo rwanda shipped organisations including provide nearly million tablets year mozambique namibia argentina bill melinda gates foundation help eliminate disabling guinea preparation activities uk department international debilitating parasitic disease spread announced extend development us agency mosquitoes work global programme beyond africa include international development usaid alliance eliminate lymphatic filariasis endemic regions meet commitments new united effort support developing continuing grow help reach invested new manufacturing countries defeat ntds coalition one billion people risk lf line factory south africa support ambitious goals set since donated billion control eliminate collective commitment donate albendazole treatments ntds end decade one billion albendazole treatments countries shipped includes eliminating five diseases million tablets lf soil year aim help countries fight billion elephantiasis intestinal worms lymphatic filariasis elephantiasis guinea transmitted helminths sth worm blinding trachoma sleeping several countries completed sickness leprosy controlling mass drug administrations lf five soil transmitted helminths albendazole treatments process confirming absence intestinal worms schistosomiasis economic benefits resulting first years donated year disease transmission overall global programme eliminate lymphatic river blindness chagas visceral commitments target economic benefit global lf filariasis plos public library science leishmaniasis ntds june volume issue lf sth infectiongsk corporate responsibility report health case study developing countries preventing disease raising awareness measuring impact phase programme every year three million people die diarrhoeal disease shows programme continuing change children spread disease behaviour reduce incidence disease easily prevented improving water quality countries implemented encouraging people wash hands personal example bangladesh number families hygiene sanitation education phase programme wearing sandals using latrine avoid worm run partnership ngos tackles issues infestations increased reduction diarrhoea incidence participating schools reduced well improving local water pipes pumps infrastructure phase teaches children wash hands important using easy understand phase recently implemented high books story cards adapted reflect density urban settlements example nairobi mumbai everyday lives country programme rio de janeiro extended partnership encourages children share learnt earth institutes millennium villages project families communities integrate oral healthcare phase poor oral hygiene significant problem developing countries since phase began programme reached least affecting individuals overall health quality life million children information aim introduce test effective measures change behaviour keep healthy behaviour change promotion good oral conducted second strategic review assess impact health practice nutrition eating habits behaviour health research carried water engineering development centre goal set model integrating phase loughborough university uk school deworming part expanded albendazole donation programme see phase global overview published website june gsk corporate responsibility report health developing countries advocacy advocacy supported development pilot advance market future plans commitment pneumococcal vaccine appropriate work governments policy believe contribute efforts presented behalf industry first meeting makers encourage changes policy environment improve health developing countries whos consultative expert working group rd help increase access healthcare sustainable continue develop product portfolio suited financing first meeting way includes working companies sector disease burden suffered patients developing foster industrywide approaches worked uk government global health issues countries also continue including cochair uks industry government support approaches encourage adequate forum access medicines participation introduce flexible pricing strategies work others investment healthcare infrastructure support partners forum uk governments global increase access middleincome countries innovation support differential pricing adequate health strategy seek partnerships encourage scientists work financing mechanisms gavi global participated executive board meetings us research centre diseases fund fight aids tb malaria factors world health assembly developing world tres cantos spain critical sustainably improving access long term participated board members gavi alliance encourage others consider innovative approaches examples include roll back malaria also participated gavi realise potential wipo research cochaired gatesceo roundtable led replenishment conference funding immunisation seek reduce prices patented medicines january ntd conference played children developing countries ldcs major role engaged intergovernmental meeting reinvest profits make selling medicines ceo sir andrew witty participated event pandemic influenza preparedness ldcs help strengthen healthcare infrastructure us state department led formation participated numerous meetings presented countries encourage others consider coalition private sector companies help tackle events access medicines intellectual property similar schemes lack frontline healthcare workers european uk parliaments venues integrate phase school deworming part participated launch gfinder report rd expanded albendazole donation programme neglected diseases read online publish detail online key issues including access developing countries public health intellectual property product donations pricing reimbursement market access wwwgskcomreportsandpublicationspoliciesgsk corporate responsibility report health developed countries ageing populations rise reimbursement medicine subject specified demonstrating value research conditions help address uncertainties incidence chronic diseases means may exist cases launch product collaborating european healthcare healthcare budgets strain performance budget impact example italy innovation leadership network ehiln improve understanding different stakeholder groups gsk reimburse costs tyverb breast many developed countries constitutes medicines value find ways cancer therapy case failure interruption better demonstrate research process therapy first weeks treatment recognise governments must balance desire participated pilot project healthcare equality need manage limited also working closely governments help stakeholders advised gsk development strategy financial resources ongoing financial crisis manage healthcare costs example czech republic earlystage diabetes product could made task increasing access products even national immunisation committee recommended refined better demonstrate medicines value challenging universal mass vaccination pneumococcal vaccines second pilot project launched december government funding available implement innovative oncology product engaged aim work closely governments payers special team set within gsk czech republic discussions eu policy makers development healthcare systems ensure products available partner payers doctors distributors epidemiologists consistent euwide approach assessing value affordable seek understand needs politicians help overcome challenge new medicines healthcare priorities make sure establish new reimbursement distribution system demonstrate full value products also established access medicines centre pneumococcal vaccination included reimbursement rd process evidencebased data time excellence within european pharmaceutical system funded health insurance companies hics launch allow fair price set business working payers healthcare systems new supply chain distribute vaccines clinics reflects medicines proven value affordable understand thinking needs insights funding system established offered volume customers sustainable gsk gathered advisory boards regular discount structure synflorix pneumococcal vaccine engagements brought rd process accepted hics still place europe ensure evidence need fully considered newborn population covered medicine development plans developing solutions europe financial crisis put unprecedented new funding distribution system healthcare system challenges clear priority pressure public budgets achieve best results direction business gsk committed helping individual eu member states patients taxpayers industry believe must manage funding gaps protecting development work genuine partner governments helping innovative valueadding medicines vaccines find solutions bring value healthcare systems european trade association efpia support costmanagement maintaining participated discussions national governments incentives innovation imf european commission european support differentiated approaches central bank agreements reached support tailored particular national context allow countries manage pharmaceutical spending one companies offer prices take affordability concerns ways work towards meeting overall account appropriate come financial commitments form innovative pricing approaches enable accessgsk corporate responsibility report health developed countries usa usa member together rx access industry tackling chronic diseases programme gives uninsured us citizens usa million people living discounts medicines gsk programme usa way healthcare delivered paid federal poverty limit many difficulty open people earn four times federal evolving gsk committed helping identify paying healthcare patients may poverty level nearly two million americans enrolled solutions improve healthcare reduce costs eligible government programmes medicaid together rx access almost patients particular focus chronic diseases others still need assistance obtain prescription received day prescriptions gsk medicines responsible healthcare costs usa medications need gsk several programmes together rx access programme giving current us system patient visits number provide medicines free eligible patients patients discounts since different specialists may aware health uninsured underinsured earn enough inception together rx access given services patient received healthcare money afford medication million patients savings totalling million across providers test results treatments patients received gsk wide range products medical conditions prescribed medications medicines vaccines worth million million also launched patient assistance programme result care become episodic uncoordinated us programmes value calculated benlysta lupus treatment developing gsk teamed community cares north using average cost goods rather wholesale codevelopment cocommercialisation carolina innovative publicprivate collaboration acquisition cost measure used pharmaceutical agreement human genome sciences makes called north carolina first health aims companies believe approach valuing medicines medicine available cost patients without demonstrate coordinated care help reduce accurately reflects true cost gsk valued insurance meet certain eligibility qualifications cost healthcare improve patient outcomes wholesale acquisition cost value medicines also launched copayment assistance participants include state health plan north us programmes would million programme help eligible patients carolina pharmacy chain kerr drug sas blue gsk operates several programmes patients meet outofpocket costs benlysta cross blue shield north carolina states largest certain eligibility requirements including commitment please see information viiv healthcares health insurer access cancer treatments bridges access us patient assistance programmes first health uses patientcentered medical home medicines outpatients vaccines access covering model means patients primary care adult vaccines hepatitis hepatitis b tetanus physician coordinates patients healthcare diphtheria pertussis cervical cancer gsk access providers using health information technology provides extra help lowincome seniors care managers provides comprehensive disabled patients enrolled medicare part picture patients health enables coordinated approach gsk enabling employees north carolina participate programme employees enrolled since began januarygsk corporate responsibility report health hivaids viiv healthcare viiv healthcare established gsk research development evaluate new approach twodrug versus threedrug oncedaily combination treatment pfizer independent viiv healthcare committed development new patients infected ccrtropic hiv company solely focused needs products target unmet medical needs hiv include treatment children living viiv healthcare supporting international hiv people living hiv longer ageing hiv tackling problems collaborative research trials resourcepoor settings drug resistance complex treatment regimens partnership broad range external organisations committed delivering innovations side effects associated current treatments academic institutes uks medical improvements people living hiv wherever viiv healthcare currently molecules research council us national institutes health world section outlines approach investigation development potential new hiv focus public health related issues progress also find online treatments including five compounds phase ii prevention mothertochild hiv transmission paediatric wwwviivhealthcarecom phase iii development adult treatment strategies start treatment hivtb coinfection viiv healthcare donates arvs viiv healthcare aims reenergise pharmaceutical joint venture shionogi viiv healthcare provides financial support well scientific input industrys participation hiv deeper developing novel oncedaily unboosted investigational throughout life study broader understanding needs live hiv integrase inhibitor sgsk known virus treat fixed dose combination trii epzicom end trials underway kivexa phase iii clinical trials continued planned involving patients twenty gsk pfizer hiv medicines marketed viiv nine trials involve one african countries healthcare broad portfolio medicines hiv simplification therapy oncedaily dosing eight paediatric studies one provide annual sales billion means priority terms patient quality life first significant clinical data efficacy safety financial stability investment capital required potentially improve outcomes october viiv pharmacokinetics viiv healthcares nrti scored tablets take sustainable longterm view hiv market healthcare launched first largescale phase iii clinical resourcepoor setting trial oncedaily dosing celsentriselzentry combination protease inhibitor hiv patients previously untreated antiretrovirals arvs molecules development trials underway end potential new involving hiv treatments patientsgsk corporate responsibility report health case study hivaids viiv healthcare research development treatment children hivaids infants children living hivaids developing joint efforts improve access therapy care include several initiatives testing hivexposed countries often access effective treatment viiv healthcareelizabeth glaser pediatric aids infants within eight weeks birth recommended launch viiv healthcare committed foundation partnership egpaf aims increase successfully scaled programme million paediatric innovation seed fund early detection hiv improve access arv therapy resulted greater numbers infants initiated support research development meet needs hivpositive infants young children strengthen antiretroviral treatment testing hiv positive patients fund supports partnerships government leadership policies around paediatric partnership catalysed new formal informal organisations focus evidence base hivaids improve quality use paediatric collaboration organisations delivering paediatric care paediatric care treatment research care partnership sought resolve critical linkages health facilities communities development paediatric fixeddose combination fdc barrier treatment children improvement also strengthened products formulations treatment infants early infant diagnosis treatment subsaharan viiv healthcareamfar treat asia programme children living hiv africa focus lesotho swaziland malawi aims optimise quality healthcare infants children living hiv across asia development clinical data support paediatric treatment guidelines since initiation treat asia partners working address knowledge gaps paediatric care treatment establishing research studies educational workshops advocacy projects nonmonetary memorandum understanding clinton health access initiative chai aimed developing affordable new fdc paediatric usegsk corporate responsibility report health hivaids viiv healthcare increasing access increasing access innovative pricing voluntary licensing viiv healthcare committed playing part viiv healthcare offers complete arv portfolio notfor royaltyfree voluntary licensing approach addressing access medicines challenges taking profit prices ldcs world banks lowincome viiv healthcare enables generics companies manufacture innovative responsible sustainable approach countries subsaharan africa countries sell versions products ldcs lowincome according unitaid cover people currently countries subsaharan africa according unaids million living hiv notforprofit price combivir estimated million people living hiv eligible viiv healthcare granted voluntary licences per patient per year cents day compared treatment low middleincome countries arvs increase eight company formed accessing antiretroviral therapy unaids licensees supplied million committed reaching million people living significant improvement affordability versions epivir combivir african countries hiv antiretroviral treatment across recognise price affordable worlds poorest viiv healthcare anticipates volumes lamivudine world total unaids estimates million people communities without significant additional healthcare licensees decrease following patent expiry living hiv low middleincome countries resources made available ongoing commitment supporting access hiv therapy fold increase since middleincome countries incomes higher affordable second line regimens viiv healthcare anticipates viiv healthcare recognises part key stakeholder infrastructure developed flexible generic versions broader portfolio endeavour global effort committed working pricing policy factors gross domestic product measure report data future reporting partnership hiv community address gdp impact epidemic country challenge industryleading access initiatives improve affordability countries include continually evaluated look fastest growing economies world supply combivir epivir tablets improvements viiv healthcares access medicines need government commitment accountability licensees approach covers mics lowincome countries scaling national response hiv epidemic ldcs subsaharan africa countries total number tablets million viiv healthcare shipped tablets notfor done variety approaches based profit combivir epivir developing countries compared differing needs people living hiv different million decline supply viiv parts world healthcares arvs expected outweighed volumes supplied licensees viiv healthcare licensees gsk licensees data include additional licensees however comparable data available data considered conservative estimate use licensees captured data data include paediatric formulations syrup viiv healthcare also aware significant use zidovudine lamivudine generic fixed dose combinationsgsk corporate responsibility report health hivaids viiv healthcare community investment local partnerships technology transfer community investment positive action children fund one approach taken viiv healthcare middleincome viiv healthcare supports communities affected hiv collaboration partners aim provide countries creating partnerships incountry aids positive action programme positive support deliver prevention mothertochild pharmaceutical companies manufacture medicines action children fund positive action community transmission hiv pmtct services every year locally bringing cost therapies grants read wwwviivhealthcareeffectcom continue form new partnerships community investing sharing expertise build skills local focused organisations striving alleviate devastating positive action programme economy partnership binnopharm russia effects hivaids pandemic positive action enables local secondary manufacture viiv healthcares positive action programme created children fund integral part viiv healthcares arvs people living hiv russia example work marginalised vulnerable communities commitment communities affected hiv aids including young people girls women sex workers company committed invest million medicines patent pool foundation mppf men sex men homeless injecting million fund years medicines patent pool one several international drug users since launch march positive action community responses meet challenge improving access treatment care people living viiv healthcare continues make great progress children fund committed million projects affected hiv aids community partnerships connections collaborations countries partner organisations demonstrate broader hiv community funding enables commitment dedication addressing mother mppf wrote viiv healthcare pharmaceutical communities tochild transmission hiv innovation companies working hiv early december maximising local resources made available asking join formal discussions pool tackle stigma discrimination reduce violence various health systems work closely aligned viiv healthcare met mppf january since risk populations unaids global plan towards elimination new hiv held several constructive meetings test innovations education care treatment infections among children keeping continue dialogue build grassroots capacity disproportionately mothers alive also works towards achieving us patient assistance programmes affected communities millennium development goals set reduce child mortality improve maternal health improve access hiv medicines uninsured low february positive action programme income patients usa viiv healthcare launched international hivaids alliance announced positive action community grants patient assistance programme hiv medicines partnership vida digna would extended el salvador positive action community grants given january programme provides viiv healthcare five additional countries central america tackling viiv healthcares local operating companies hiv hiv products little cost qualified patients stigma discrimination vulnerable populations community organisations support innovative household income us federal poverty people living hiv programmes read case study one level viiv healthcare also piloting membership programme germany beats life online usa positive action southern initiative welvista nonprofit programme facilitates access extended eight states collaborative hiv medications currently waiting list communityfocused programme designed address us governments aids drug assistance program gaps services programmes support care treatment address improving adherence among individuals living hivaidsgsk corporate responsibility report health case study hivaids viiv healthcare community investment vijana tunaweza newala globally girls young women followup study showed project likely hivpositive male helped bring changes attitudes peers viiv healthcares positive action towards sexual relationships programme funded project stimulated dialogue girls rights newala one least developed role society local poorly resourced districts tanzania communities provide tackle fundamental causes girls educational support girls vulnerabilities hivaids project vijana tunaweza newala research project identified four run international center key sources vulnerabilities research women icrw taasisi gender stereotyping erosion family ya maendeleo shirikishi arusha social support networks exploitation tamasha collaboration pact early sex limited communication tanzania viiv healthcare currently support project launched discussing ways expand reach life skills education programme providing programme icrw opportunities girls talk sexual community partners tanzania reproductive health empowerment selfawareness social personal issues sixmonth pilot period sessions held schools local communities reaching young people information pregnancy hiv self esteem puberty love sex goal setting forming friendshipsgsk corporate responsibility report people contents introduction performance communities working gsk feature bringing engaging employees science london olympic developing employees paralympic games supporting development diversity gsk pulse employee health safety volunteering people communities community around world investment respect click arrows go section people support employees reach full potential aim make positive difference communities operate economic contribution investment education programmes partnershipsgsk corporate responsibility report people communities introduction investing people employment practices designed create work progress place culture gsk employees feel valued communities underpins long term respected empowered inspired achieve goals continued focus diversity inclusion sustainability business creating senior managers women strong prosperous communities create right total workforce employed emerging markets right internal external conditions business growth want catalyst asia pacific japan regions change helping many communities work conditions support strategy extended employee assistance programme eap flourish business grows employees providing access counselling mental health emotional crisis support reduced days lost injury illness per hours worked set new reportable injury illness target engaged employees idea engine facility generated ideas improving aspects business performance valuesbased business extended pulse programme give employees countries chance contribute skills nonprofit organisations placements gsk values guide work expect used involvement london olympic employees paralympic games inspire new generation young scientists improve health wellbeing commit transparency communities employees show respect people gave million global community investment including million product donations valued demonstrate highest integrity conduct cost patientfocused donated products valued million areas affected japanese earthquake million read apply values cash japanese red cross gsk corporate responsibility report people communities working gsk aim create inclusive inclusive environment good business myceo section global intranet gives employees brings different knowledge perspectives experiences chance pose questions sir andrew witty engaging working environment working styles enhance creativity members corporate executive team cet many empowers employees contribute innovation gsk gsk employs people cet members blogs qa pages update staff countries worldwide parts business also communicate help us achieve strategic facetoface meetings webbroadcasts regular aim every gsk employee feel engaged business objectives key broadcasts sir andrew screened gsk locations work colleagues understand impact available watch employees computers investment development delivery business objectives approach flexible working performance know one key motivators using idea engine facility employees make employees contribution makes positive suggestions improving aspects business innovative safety health impact peoples lives giving real sense purpose performance vote ideas put forward colleagues wellbeing programmes ran campaigns generating ideas engaging employees votes campaigns covered range themes engaging employees new strategy believe relationship employee consumer healthcare business ideas line manager critical factor ensuring improving customer service new core business employee engagement leadership programmes services function manager training every level aim build leadership capability seek feedback managers last years seen major changes business performing leaders employee survey including new acquisitions joint ventures degree feedback processes restructuring including outsourcing site closures staff senior leaders took part degree assessment reductions markets global footprint receive feedback performance changed reduction number employees supervise well colleagues managers peers western markets increase employees based emerging markets communicate regularly employees order provide uptodate information progress towards conscious effect restructuring goals changes business listen employees whenever possible aim achieve feedback stimulate innovative ideas organisational financial goals without eliminating jobs consult employees representatives made improvements internal communications implementing measures affect workforce example improving connectgsk global intranet site help people obtain information quickly programmes energy performance team connect colleagues across company personal resilience help employees sustain energy levels especially times changegsk corporate responsibility report people working gsk developing employees communities developing employees pay performance want gsk employer choice achieve open transparent reward total remuneration executive directors invest significantly developing employees every employees management executive team including value awards earned level people early careers senior longterm incentive plans total remuneration management positions offer employees recognise reward employees contribution includes base salary benefits pay range learning opportunities tailored development success business offer competitive salaries performance elements annual bonus value programmes employees achieve sustainable based industry benchmarks incentives longterm incentive awards committee high performance encourage onthejob learning acknowledge performance annual objectives want reward failure payment performance challenging project work supported company performance share ownership schemes principle ensures incentive payouts made formal training programmes mentoring coaching management executive level remuneration aligned circumstances performance outcomes reflect well volunteer programmes pulse business performance measures supports genuine achievements original targets number development programmes delivery strategic priorities emphasis level total remuneration could earned support new recruits early careers including rewarding longterm performance packages granted executive directors industrial placements apprenticeships esprit remuneration committee sets remuneration policy final values determined three years global mba programme postgraduates updated levels executive team giving consideration time actual performance measured university relations strategy make sure levels wider employee population targets however number scenarios included access greater numbers talented graduates supporting responsibility ensuring appropriate demonstrate range remuneration ambition increase graduate recruitment threefold excessive competitive industry wider could achieved people per year market norms policy structured pay committed reimbursing uncapped tuition fees aware sensitive environment surrounding performance based set consistent rigorous undergraduates recruited uk executive pay time real economic challenge standards reward achievement strategic onwards investment future company priorities designed ensure delivery strong one britains largest companies recognise broadly uk industry young people longterm financial performance sustainable leadership role importance balanced recently introduced job coaching programme shareholder value approach also important gsk like multi hr business leaders coach colleagues national companies able compete globally continuously evaluate approach consult direct line management trained reward leadership vision fundamental key shareholders annually proposals policy job coaches coach approximately success continued success interests listen carefully feedback believe employees countries also introduced shareholders global economy current approach reflects year practical coaching workplace oneday enhanced disclosures annual report provide programme designed help managers adopt transparency clear overview total coaching culture teams believe focus remuneration earned available executive coaching help us create energised directors includes resilient workforce highperforming leadership sgs verifiedgsk corporate responsibility report people working gsk diversity communities leadership development framework supports diversity gsk women management positions critical career stages building leadership pipeline provides clarity around skills capabilities inclusive employer helps us attract retain required key stage extending attendance motivate workforce reflects communities svp vp leadership programmes employees operate director emerging markets example manager committed making employment gsk accessible participants leading business programme total people disabilities increasing proportion potential general managers emerging markets women people emerging markets management ethnic minorities uk usa employees first line leadership programme delivered positions measure proportion women languages countries management positions worldwide proportion future strategy group fsg proved valuable ethnic minority employees uk usa uk opportunities high potential employees work closely usa aim people disabilities able access full corporate executive team employees range recruitment career opportunities partner proportion people employ emerging undertook assignments challenging areas access disability organisations employers forum markets asia pacific japan regions increased medicines malaria gaining valuable experience disability uk sermes spain total employees around thinking operating enterprisewide level signed employers forum disability accessible senior managers report executive team thinking flexibly way work enables us technology charter supported blue chip came regions plan increase attract retain critical talent groups include organisations government departments charter formal arrangements flexible hours parttime aims improve access people disabilities ethnic minorities accounted uk employees working job shares well informal arrangements spur inclusive design proportion ethnic minorities england wales census based working different locations empowers good representation women management uk commission racial equality definition employees helping optimise effectiveness positions percentage women higher level encompasses identify better balance work needs positions grew reflecting goal increase white british also measure diversity uk commitments encourage flexibility provided also proportion female employees senior levels number employees define nonwhite meets broader needs business employees nonwhite compared aspiration female representation board currently three women serving nonexecutive directors usa ethnic minorities defined black representing board three women african american people hispanic latino people corporate executive team asian people pacific islanders american indian people alaskan natives proportion ethnic minority employees usa increased continue work towards industry average defined north american industry classification system pharmaceutical medicine manufacturinggsk corporate responsibility report people working gsk health safety communities health safety seven strategic ehs priorities resilience latin america health safety management integrated gsks gsks latin america region used team resilience healthy improving health employees environment health safety ehs strategy supports programme energy performance ep workshops sustainable families disease business objectives reducing risk harm significantly reduce perceived workplace pressures lives prevention health promotion helping employees healthy productive energised country region introduced team strategic review completed set new ehs resilience programme following success sales energised aspirations healthy resilient highperforming force brazil employees helping employees manage resilient workforce achieving zero harm people benefited since personal health sustainability workers environment identified seven strategic priorities participated ep achieve programme enables employees engage sustaining high providing coaching help people ceo ehs sustainability awards key tool manager reflect way work analyse performing perform best developing engaging employees health safety environmental pressure points identify action improve resilience leaders solutions resources issues refreshed awards reflect new employees perceive lower pressure six read strategic priorities particular recognised projects seven categories showed demonstrable benefits business healthy high enhancing working strategic areas year received applications responses citing low mediumhigh pressure latin america performing environment improve winners featured workplaces quality working life planet section work demands healthy resilient highperforming workforce culture zero serious gsk provided programmes positive impact eliminating serious incidents accidents improving peoples wellbeing productivity control several years programmes tools resources help employees lead healthier lives cope better management practices embedding putting right values stresses may experience work home ehs beliefs p tor ec mtic es tt h eh c ino r te h e f w au yr wcu elt ure pilot new preventive healthcare services career development behaviours programme employees families business relationships environmental reducing environmental individual characteristics sustainability footprint read low mediumhigh sgs verifiedgsk corporate responsibility report people working gsk health safety communities emotional mental health ability cope aiming zero harm ceo awards pressure important physical wellbeing aim zero harm immediate aspiration employee assistance programme eap provides gsk zero serious incidents employees access counselling mental health resilience emotional crisis support extended eap risks employees vary according roles include employees beginning chemical exposure driving accidents repetitive strain gsk taiwans energy performance programme year injuries operate rigorous procedures eliminate ceo sustainability award healthy hazards practicable protect employees highperforming workforce programme energy resilience programmes help individuals necessary right culture essential starting strengthened personal team resilience teams effective increasing focus point living safety programme initially launched highprofile holistic programme results included energy confidence reducing tension anxiety aims change perception safety fatigue additional employees participated halving employee turnover rate integrated operations increase personal one resilience programmes bringing responsibility safety living safety module zero harm overall participation nearly employees intranet provides interactive tools improve employees rd manufacturing teams ware uk energy coaching new programme oneon understanding risks manage evreux france zebulon usa jointly one telephone coaching three sessions reducing health safety risks ceo sustainability award zero harm project coach helps employees identify energy needs automate analytical testing dry powder evaluate options address revitalize took steps improve risk recognition injury another new programme intranet tool root cause assessment general safety capabilities inhalers results included reduced exposure analysts employees learn recognise manage throughout gsk particular emphasis solvent active ingredients risk repetitive emotional stress mental distraction machine process construction safety also strain injuries improved data quality consistency launched professional certification programme improved throughput efficiency energy resilience programmes measurable improve health safety skills ehs workforce impact employee behaviour analysis found help us fill ehs talent shortages developing participants improved aspects desirable markets support ehs goals behaviour acting coach mentor setting specific targets also reported improved lifestyles hazardous materials used development especially nutrition resulting feeling healthier manufacture pharmaceuticals continue key risk energetic example followup study gsk operations see threeyear process safety canada demonstrated employees increased plan aims identify reduce risk train personnel engagement work following energy key process safety elements improve performance performance saying programme improved instance primary manufacturing sites use job performance much three years later process safety performance indicators number severity incidents ensure risks well managed sgs verifiedgsk corporate responsibility report people working gsk health safety communities launched process safety programme respirator free ongoing initiative use engineering alert approach halves injuries secondary consumer manufacturing programme process related controls reduce occupational identifies potential major hazards develops risk reduction exposure risk harmful airborne powders clifton new jersey site usa halved rate plans provides process safety training reviews completion projects tasks involving injury illness creating paradigm key control systems completed process safety powder handling manufacturing facilities shift changed employees approach near miss diagnostics secondary consumer sites respirator free incidents employees decided replace term near covered end miss safety alert term likely grab raising employee awareness importance health attention provoke action routinely perform audits ensure reducing safety commercial sales operations managing risks effectively challenging diverse group work site director challenged employee submit internal audits main themes control environments diverse geographies situations least one safety alert quarter achieve total high risk nonroutine activities process safety ranging offices london sales forces year compared monitoring systems control pathological agents motorbikes india needs assessment field thinking alerts would lead audits found management health safety groups led development specific training action preventing accidents risks generally adequate identified progress tools road driver safety also launched employees responded enthusiastically submitting process safety risks machinery safety found awareness campaign risks injury slipping alerts year importantly improvement needed issues relating risk falling one greatest contributors injury safety improved site went nearly six months management processes selfinspection related work loss without reportable injury monitoring systems ergonomics addition internal audit work enhancing site made exceptional progress recent years audits help identify control health safety risks improving ergonomic programme continue audits carried site employees help increase employee awareness ergonomics website build better risk assessing monitoring culture encourages sites submit solutions trained employees carry sitebased audits ergonomic problems creating library examples manufacturing sites help sites similar situations next step philosophy zero access machines adopted beginning replace existing risk assessment manufacturing sites resulted decrease applications single system appropriate significant risks related operation production open office design machinery zero access aims eliminate serious injuries harm employees related machine safety ensures protective machine guarding place lockouttagout loto processes use protect staff operations however even protective measures place three employees suffered amputations sgs verifiedgsk corporate responsibility report people working gsk health safety communities health safety performance fines penalties reportable injury illness rate work related fatalities serious injuries health safety fines penalties assessed gsk per hrs worked keeping employees contractors healthy safe priority essential part responsible injury illness target employer regrettably two employees died set new target performance one pakistan feeling unwell offsite demonstrates started make progress training programme second employee died another expect trend continue expansion seriously injured car travelling living safety programme use leading ambushed nigeria leading causes gsk reportable injuries performance metrics measure performance illnesses following serious incident review assess broad picture injury illness causes remains processes build guidance give previous years top three leading employees guidance recognising responding slipstripsfalls causes slipstripsfalls machineryrelated injuries heart symptoms shared globally machinery musculoskeletal conditions eg repetitive stress strain advice measures reduce carjacking risks motor vehicle accidents motion cases mental illhealth account less provided employees nigeria sprainsstrains incidents continue musculoskeletal condition performing routine activities sites india highest number lost calendar days egypt two operators suffered amputations moving detailed breakdown metrics data machinery another employee india suffered finger please see detailed download available online amputation motor vehicle accident zero environment health safety data cr report access driver safety approaches critical assured sgs uk read assurance statement preventing machine road safety related serious response injuries harm employees sgs verifiedgsk corporate responsibility report people working gsk health safety communities summary injury illness data ehs plans targets working four priority areas hours worked millions enable sustainable business performance fatalities reduce reportable injury illness rate number injuries illnesses lost time year end enhance ehs calendar days lost leadership capability engagement expand number injuries illnesses without lost time living safety improve driver safety programme losttime injury illness rate produce simplified ehs management tools per hrs worked risk reduction simplify ehs standards calendar days lost rate per hrs worked policies revise ehs governance structure reportable injury illness rate introduce predictive ways reduce risk develop per hrs worked illhealth absence risk reduction strategy notes behaviours values launch ehs data cover employees contract workers directly engagement programme drive new ambitions supervised gsk employees report snapshot injury illness performance year cases may added end year develop leading metrics give advance warning prior years may change risks basis targets set losttime injuries illnesses workrelated injuries illnesses include ehs culture index metric serious enough result one days away work based near miss reporting prevent lost calendar days days including weekends employees serious incidents could work workrelated injuries illnesses helps provide measure severity injuries illnesses ehs operating model enhance ehs critical reportable injuries illnesses without lost time incidents capabilities assess fill competency gaps result time away work serious first aid serious enough result lost time also aim rapid adoption best practices increased global consistency identify read online address gaps publish positions online including hazardous chemical management gsk eu reach regulation wwwgskcomreportsandpublicationspoliciesgsk corporate responsibility report people communities community investment community investment aims maximise benefits community investment responding japanese earthquake working partnership ngos selecting improve health education increase projects enable us use expertise resources following earthquake devastating tsunami access medicines healthcare well benefiting communities investment japan march gsk japan mobilised team strengthens business improving reputation orange employee volunteers delivered food services target support boosting employee morale helping us build blankets face masks emergency products make difference relationships based mutual understanding people colleagues affected areas tohoku range stakeholders district employee fundraising campaign raised support ongoing reconstruction approach includes funding innovative programmes programmes support designed long recovery efforts improve health community engagement term sustainable impact set ambitious commitments behavioural change donating medicines expertise work experienced partners also contributed essential medicines gsk reinvesting profits improve healthcare consumer healthcare products affected areas infrastructure also invest science education read health section report valued million donated million cash support relief efforts following natural disasters includes details progress commitments japanese red cross also responded quickly longterm albendazole donation programme make sure minimal disruptions targets two neglected tropical diseases elimination product supply see detail lymphatic filariasis lf also known elephantiasis created orange scholarship fund treatment children intestinal worms support students affected earthquake reinvest profits make least developed thirty students studying pharmacy two universities countries ldcs back healthcare infrastructure tohoku started receiving scholarships yen partnering three leading nongovernmental approximately per month graduation organisations ngos address shortage trained help continue studies university frontline healthcare workers personal hygiene sanitation education phase programme run partnership ngos aims reduce diarrhoeal disease improving water quality encouraging people wash hands also encourage employees get involved volunteers orange day pulse initiatives read thesegsk corporate responsibility report people community investment performance communities performance half cash giving million targeted giving health programmes includes partnerships global community investment million amref care international save children support million overall giving remained constant training frontline healthcare workers part cash excluding oneoff commitment reinvest profits made least product donation million doses hn vaccination developed countries read inkind world health organization use developing publish data charitable grants management countries patient groups grants online total value donations cost average cost goods rather us patient assistance programs account almost wholesale acquisition cost wac measure used half overall giving read companies believe detail several factors impacted accurate reflection true cost gsk belong us programmes expect breakdown cash giving uks london benchmarking group lbg us continue include removal several committee encouraging corporate philanthropy cecp branded medicines given commercial availability lbg guidelines report product donations cost whereas lowcost generic products fall patient enrolments health cecp guidelines report product donations market due changes medicare part switch education value benchmarking purposes also report retail mail order reduced overall programme arts culture wac value donations total value costs included figures environment global giving using wac product donations ldc reinvestment million million participation pulse programme continues increase million invested pulse product donations cost million made volunteers continue receive full gsk salary three main programmes placement along programme operating costs us patient assistance programs support lowincome represent million inkind donation also help heroes patients usa million began investment olympicsrelated community humanitarian product donations million programmes scientists sport personal best read next donation albendazole tablets lymphatic uk gsk supporting new phoenix wellness filariasis lf elimination programme million viiv healthcare doubled giving centre tedworth house personnel recovery million million driven assessment centre tidworth salisbury injured read policy principles underpin approach product donations online expansion us patient assistance programme servicemen women charity help continued funding paediatric innovation seed fund heroes providing funding million positive action children fund read next five years support programme gsk corporate responsibility report people communities feature bringing science london olympic paralympic games using excitement generated london olympic paralympic games opportunity advance scientific progress inspire new generation young scientists improve health wellbeing communities employees achieved official london partnership also going beyond commitment create positive lasting legacygsk corporate responsibility report people feature bringing science london olympic paralympic games communities promoting fair play advancing scientific progress inspiring young scientists improving health wellbeing community official laboratory services provider london inspired gsk create scientists using london opportunity improve london games contributing expertise sport school outreach programme jointly developed health wellbeing community initiatives research development support integrity kcl uk antidoping ukad helps personal best initiative nhs games health athletes scientists kings year olds understand role science play london help deliver health legacy london college london kcl use new world anti games excites potential science inspiring million people aged doping agency wada accredited laboratory established careers children visit university participate longterm health conditions lead gsk test use performanceenhancing drugs activities hear science used sport active lifestyle games helping recruit time running ukwide challenge motivating employees phd students support kcl antidoping schools endorsed british science association experts analyse samples used london partnership teams design portable antidoping kit tested previous games gsk currently working recognise gsk employees make positive difference test new substances developed kits secure sustainable future laboratory using ticket allocation gsk science ambassadors use outreach hope could operate standalone business olympic paralympic games reward employees programme range free resources teachers beyond games gsk also selected employees demonstrably living joint gsk olympic pupils available wwwscientistsinsportcom manage antidoping control centres paralympic ideals integrity equality friendship ambition reach every secondary school olympic paralympic venues athletes excellence uk get thousands schoolchildren participating provide samples programmes continue help fight doping games committed supply wada confidential information medicines early stage development potential abused athletes allow develop testing techniques medicines even marketed official laboratory services providergsk corporate responsibility report people community investment pulse employee volunteering communities pulse employee volunteering six months completing pulse nearly major volunteer programme orange day gives volunteers said energised employees one paid day year volunteer contribute time expertise well money work gsk eightythree per cent volunteers team chosen local community project year thousands products create positive change communities members gsk said pulse enabled volunteers us staff volunteered part national day service operate two volunteer programmes share different external perspective helped remembrance tenth anniversary pulse orange day provide employees inform shape gsks work thinking policy activities included packing meals opportunity make impact develop ngo managers said people haiti kenya nicaragua flood victims knowledge capabilities volunteers impact sustainable six months usa national day initiated mygooddeed pulse gives employees chance join nonprofit pulse assignment ended charity founding sponsor nongovernmental organisation ngo three recent international corporate volunteering six month fulltime placement enables employees benchmark study independent organisation leadership potential develop professional skills pulse emerged topofclass compared new challenging environments helping partner international corporate volunteering organisations develop implement strategic plans programmes pulse differentiated peer improve processes operations enhance programmes breadth scope duration communications marketing assignments well incorporating rigorous processes worked pulse partners supporting measuring impact partner organisations gsk organisations work healthcare education volunteers environmental issues areas great need evolve programme launch three proven track record started new partnerships pulse pillars focus multiyear multi ngos including care international jen volunteer projects strengthening contribution japanese emergency relief charity philadelphia three areas malaria access health children education fund pulse volunteers continue improve measurement help volunteers coming countries us better understand impact pulse countries nearly employees increase diversity pulse volunteer ngo pulse volunteers pulse partner countries served pulse volunteers since participants continue support pulse since organisations local hub japan establish pulse local hubs latin america indiagsk corporate responsibility report people case study community investment pulse employee volunteering communities impact awards annual impact awards recognise small awards open charities annual mediumsized charities providing excellent turnover less million uk innovative local community healthcare uk million usa well prize philadelphia raleighdurham regions money impact assessment offers feedback usa advice winner help strengthen management plans step forward received overall winner uk impact awards charity provides uk winning highly commended free confidential advice personal development organisations invited become part impact services disadvantaged young people around awards development network set connect tower hamlets london winners received winning charities provide five days included bryncynon strategy cynon organisational development training training valley wales develops innovative ways funded hosted gsk facilitated kings improve public health services deprived community fund years experience training senior affected loss local coal mining industry leaders health sector usa awards given organisations year included housing new hope helps homeless people access healthcare services part integrated approach homelessness phoenixville healthcare access foundation assists uninsured underinsured lowerincome individuals obtaining dental vision prescription servicesgsk corporate responsibility report behaviour contents introduction clinical research ethical conduct patient safety preventing bribery supply chain behaving open corruption supply marketing products distribution process honest manner feature changing supplier standards way incentivise performance sales teams usa security supply publishing payments supplier diversity healthcare professionals public policy publishing grants patient advocacy donations trade industry training awareness associations monitoring public policy activity compliance political contributions data privacy lobbying expenditure research practices patient advocacy animal research human rights building strong valuesbased culture recognise click arrows need go section open challenges face actions backed robust policies strong compliance processesgsk corporate responsibility report behaviour introduction commitment responsible ethical conduct committed performance progress integrity building strong valuesbased valuesbased business underlies culture developing robust policies compliance developed new sales models decoupling pay everything including processes employing right people clear sales representatives usa number stand helping making prescriptions issued conduct report research ethical decisions updated global code practice promotion sales marketing practices customer interactions bringing greater consistency research practices investment rd core lobbying policy activities operating practices across company business essential meet consistently relationships suppliers high ethical quality standards publication payments grants donations made recognise aspects research healthcare professionals organisations usa raise ethical concerns aim open continue work towards disclosure set high standards employees address markets policies compliance programmes expect r eached agreement principle standards suppliers contractors supply chain effective responsibly managed us government conclude number ongoing business partners importantly building supply chain essential us provide medicines investigations sales marketing practices culture decisions guided values products patients consumers aim settlement payment billion necessary transparency respect people integrity work responsible suppliers set expectations step towards resolving longstanding matters patientfocus standards ethical conduct labour practices reflect company today protection human rights environment health safety management performance reduced number animals used compared public policy patient advocacy developed new scientific engagement policy public policy activity support legislative measures standards reinforce clear distinction programmes support scientific innovation balance scientific dialogue promotional activity interests business stakeholders ensuring reflect values engage also work patient professional groups help others members gain stronger voice healthcare new commitment disclose results summaries human rights committed upholding investigational medicines clinical study universal declaration human rights core labour completion rather approval termination standards set international labour organization asset signed un global compact aim act conducted clinical quality assurance assessments responsibly across spheres influence including covering gsk external research carried employees suppliers local communities society behalf broadly improvements made patient safety system databases monitoring gsk corporate responsibility report behaviour ethical conduct ethical conduct priority gsk preventing bribery corruption antibribery corruption programme audited pricewaterhousecoopers concluded failure uphold high ethical tolerate bribery corruption make risk area well managed recommended standards erode trust clear preventing corrupt practices policy enhancements related due diligence code conduct performance reviewed monthly procedures antibribery corruption training company products damage head governance ethics assurance programme implement recommendations reputation result serious legal department established anti bribery corruption expert forum meets every financial legal consequences two weeks answer employee questions advise employees read antibribery policies access antibribery corruption issues members antibribery handbook elearning module via code conduct sets fundamental standards forum include representatives antibribery intranet elearning training mandatory employees supported employee guide corruption team legal compliance functions managers employees working certain functions business conduct available languages helps well business representatives minutes meetings legal department regions employees make ethical decisions emphasises distributed members forum well higher risk corruption supplemented values transparency respect people integrity compliance officers convey key messages face face training employees high risk roles focusing patient employees new guidance documents created end employees taken result issues discussed also posted training read antibribery compliance programmes aim embed valuesbased intranet site employees visit corruption handbook online culture gsk launched one compliance initiative improve consistency policy enhanced screening process reduce introduced antibribery corruption audits implementation monitoring across business bribery corruption risks associated use frequency timing determined regular units different countries operate third parties including distributors consultants risk assessments designed provide assurance work gsks behalf markets screening bribery corruption risks adequately includes background checks designed identify managed policies procedures mitigate potential issues associated third parties higher risk working effectively audits focus areas risk categories instance acting behalf pose high risk bribery corruption perspective gsk interacting government officials including travel entertainment expenses petty cash agree business issues raised use consultants screening must addressed may mean proceeding proposed relationship insertion additional contractual clauses enhanced monitoring training third partygsk corporate responsibility report behaviour ethical conduct marketing products marketing products global code practice promotion also strengthened number commercial practice customer interactions policies usa including enhancing oversight market prescription medicines vaccines review educational reprints publications healthcare reflect commitment consistently high standards healthcare professionals hospitals governments economic information materials used sales marketing reviewed updated people concerned marketing pharmaceutical promoting medicines us pharmaceuticals business global code practice promotion customer companies may exert undue influence doctors sales introduced new policy governing support usbased interactions code covers areas representatives may always give doctors full information nonprofit healthcare organisations centralised providing information fees service payments products promoting may management funding support healthcare professionals samples hospitality grants promotion medicines unapproved uses existing donations rolled published directtoconsumer marketing policies updated global code practice promotion website employees contact healthcare customer interactions forbids practices advertise prescription medicines directly professionals including sales marketing staff unethical conduct reinforce policies consumers usa new zealand bangladesh trained standards revised code training compliance procedures making sure south korea directtoconsumer dtc advertising way pay sales teams reinforces values regional local policies standard operating prescription medicines permitted markets read remuneration sales teams overleaf procedures codes provide additional guidance promoting use prescription medicines directly employees reflecting differences regulations market recent years fundamentally changed consumers subject criticism believe structures national healthcare systems procedures compliance marketing selling responsible pharmaceutical advertising useful source least stringent global code regions usa ensure operate high standards health information patients helps increase countries may restrictive review integrity conduct business openly knowledge conditions educates patients update countryspecific codes make sure transparently reached agreement principle treatment options dtc advertising usa incorporate requirements new global code us government conclude number ongoing reviewed legal regulatory medical specialists practice promotion customer interactions investigations sales marketing practices new dtc television advertisements submitted settlement payment billion final settlement strengthened standards governing us food drug administration review corporate integrity agreement expected share scientific clinical data medicines comment prior broadcast address civil criminal liabilities groups developing well already available took decision stop television advertising sales marketing practices remains subject ongoing patients ensure clear distinction usa erectile dysfunction medicines although negotiation expected finalised appropriate scientific dialogue legitimate promotional advertising legal made decision significant step resolving difficult longstanding activity new standards introduced april longer advertise medicines television legal matters reflect company referred scientific engagement impact respect viewers today fully committed ensuring appropriate way engage scientific activities advisory promotion medicines standards rightly boards publications scientific congress activities expected us medical education read standards gsk corporate responsibility report behaviour feature changing way incentivise sales teams usa sales teams play important role providing physicians prescribers uptodate information safety benefits medicines vaccines information helps doctors make informed treatment decisions patients critical everything representatives say line values puts interests patients first gsk corporate responsibility report behaviour feature changing way incentivise sales teams usa developed new sales models align new model incentivising sales representatives changing market expectations customers work directly healthcare professionals aims example modified structure reward well sales representatives support us sales team first company customers needs achieve better patient outcomes decouple pay sales representatives rather basing bonuses individual territory usa number prescriptions issued based sales goals instead measuring performance individual sales targets assess performance past multiple sales professionals assigned determine bonuses three factors selling competency different products might call physician health customer evaluations overall performance plan many cases one person may responsible sales professionals business unit customer portfolio products bring specialists business needed change aligns incentives values provide support transparency respect people integrity patient focus shared information new model factors change aligns changing healthcare others including us government environment usa physician practices hospitals consolidating decisionmaking europe also changed way reward increasingly centralised believe new approach pharmaceuticals field sales staff replacing individual sales assess performance us sales representatives puts us strong position meet greater demand targets basis reward qualitative criteria patients healthcare providers payers higher overall business financial achievement individual quality care lower costs better health outcomes indexed performance measuresgsk corporate responsibility report behaviour ethical conduct publishing payments healthcare professionals publishing payments beginning signed statement training awareness number leading healthcare companies healthcare professionals association british pharmaceutical industry training awareness programmes help employees make payments healthcare professionals hcps abpi committing report payments uk annually understand importance ethical conduct help participate scientific conferences speak aggregate level begin payments applying policies practice hiring new meetings conferences behalf gsk products made cover payments made healthcare recruits carry preemployment checks ensure disease therapy areas relevant us sit professionals speaking advisory services well share gsks values include questions ethics provide expertise gsk advisory panels conduct sponsorship ukbased company use integrity guides used gsk sponsored research services valuable basis global standard across gsk employee interviews business improving patients health gsk continuing report payments named individual new employees complete induction training believes professionals fairly compensated level usa gsk code conduct specialised training provide services expertise us however payments provided employees working rd manufacturing publishing grants donations must excessive support must never sales marketing additional inducement reward prescribing products gsk regularly asked make grants donations regulatory requirements committed publishing payments make healthcare organisations support range activities examples training included launch hcps usa payments made hcps grants monetary contributions may used performing integrity programmes new staff speaking advisory services published quarterly fund attendance organisations hcps usa quarterly training us senior employees us website first three quarters gsk medical scientific meeting covering expenses leading integrity also updated coaching paid healthcare professionals total million support research support independent medical tool us sales employees include four questions excluding research development payments fourth education programmes donations nonmonetary values compliance help supervisory staff better quarter figures published march contributions medical equipment textbooks assess ethical behaviour sales teams read commitment benefit patients healthcare organisations updated personal development programmes disclosure research payments made healthcare separately make community investment grants usa include performance development objectives professionals institutions product donations included disclosure relating employees implement values made commitment publish payments community investments grants made require managers employees interact services grants donations made healthcare patient advocacy organisations covered later healthcare professionals confirm annually professionals organisations outside usa section comply ethics policies certification process remain fully committed disclosing publish grants donations usa every quarter supplemented new training programme payments however achieving challenging systems us website committed extend employees increase awareness introduce processes country need aligned help us grants donations outside usa align collate data across different systems multiple currencies disclosure grants donations outside working create introduce appropriate usa aggregate level time frame processes ensure effectively disclosure payments made healthcare professionals accurately enable robust complete reporting outlined publishing figures grants consistently across company taken donations made decision delay disclosuregsk corporate responsibility report behaviour ethical conduct monitoring compliance monitoring compliance addressing misconduct believe increases seen employees disciplined due introduction managers must ensure compliance company contacts made attendance payroll category policies areas responsibility corporate ethics compliance channels included attendance issues mainly reported ethics compliance department monitors tracks enquiries requests information guidance manufacturing business implemented allegations suspected legal ethical policy infractions well allegations misconduct made via line managers tighter controls ensure maintain build ensures allegations appropriately investigated compliance officers confidential reporting lines strong track record compliance additionally disciplinary action including dismissal offsite post office box usa continued focus manufacturing quality seen reporting relevant external authorities taken increase disciplinary numbers necessary serious violations policies employees disciplined policy violations good manufacturing practicegood distribution reported audit risk committee board practice gmpgdp category time period dismissed agreed leave expanding network compliance officers company voluntarily known separations categories remained broadly consistent deputy compliance officers business units time disciplinary actions included documented regions roles closely aligned warnings types policy violations businesses working identify monitor business product specific risks early strategy disciplinary actions included cases phases work mitigate risk outset projects employees breaching sales marketing codes attendance payroll increase independence compliance teams cases resulted seven dismissals separations gmpgdp compliance officers funded report directly company remaining cases resulted falsification documents corporate ethics compliance department documented warnings code conduct rather local business unit addition appropriate discipline employees staying marketing employees encouraged seek help ethical issues company receive retraining increased promotional activities report concerns suspected cases misconduct monitoring cases retraining extended policy violations line manager corporate employees colleagues prevent making total violations ethics compliance department compliance officer similar mistakes gmpgdp relates good manufacturing practice compliance champion gsks human resources legal good distribution practice departments global confidential reporting line us integrity helpline global confidential reporting line available different languagesgsk corporate responsibility report behaviour ethical conduct data privacy breaches external codes data privacy plans collect information centrally breaches external data protection security continues high part one compliance initiative industry government promotional codes priority gsk established global privacy establish compliance advisory service advise commercial businesses breach defined sales principles ensure personal data collected senior leaders business risk associated marketing infraction violation law obligation used processed transferred stored appropriately emerging business strategies responsible code standard resulting fine censure gsk securely line legal requirements promoting valuesbased compliance culture within government agency industry association breaches created global privacy office oversee privacy business also enhance compliance usually available publicly industry group regulator processes communicate best practices throughout gsk operations functions investigation capabilities websites often published local news media continuously improve compliance efforts began implement binding corporate rules found breach external codes times standards data privacy improve efficiency us pharmaceuticals business created times included transfers personal data within company implement controls centre excellence breaches country specific regulations codes increase confidence security personal data ensure alignment compliance majority related new consumer product entrusted binding corporate regulatory requirements company policies marketing promotion regulations introduced rules european commission approved approach mitigate risk enhance governance address current local ministries health enabling companies transfer personal data affiliates anticipated needs effort drive accountability located outside european economic area compliance businessdriven controls centralise monitoring inappropriate promotion pharmaceutical products uk european data protection regulations reporting support business build enhance related strict regulations binding corporate rules cover personal data held controls capability advertising materials promotion pharmaceutical employees research subjects healthcare products local operating companies must professionals partner research adhere read online epsilon one marketing services suppliers fully investigate every breach external code target malicious attack customer g sk code conduct take steps prevent reoccurrence may personal data stolen including names email include retraining corrective action including addresses gsk one companies affected e mployee guide business conduct disciplinary action aim continually improve security breach ntibribery corruption programme handbook processes ensure compliance industry codes ntibribery corruption programme third party government regulations data breach incident response team assessed guidelines situation notified every gsk consumer affected email within days incident set hotline g sks preventing corrupt practices policy questions complaints advised consumers gsk marketing practices lookout unusual suspicious emails wwwgskcomresponsibilitygsk corporate responsibility report behaviour research practices essential meet consistently ensure apply recognised standards principles animal research good medical science integrity ethics discovery high ethical quality standards development marketing gsk products animal studies remain small vital part research development system principles policies accountabilities known research many cases method medical governance framework ensures used demonstrate effects potential new parts business medicine living body tested humans patient safety fundamental operating principle countries operate animal research also provide vital information ahead commercial interests causes diseases diseases may develop research conducted objective scientific safety regulations require us test new medicines patient safety always priority evaluate ethical manner protects informs patients animals evaluated clinical trials benefits risks medicines stages research prescribers payers countries require additional animal testing new product approved sale also promotional practices information provide market even though medicines committed transparency disclosing results products ethical accurate balanced approved use elsewhere clinical research meet legal regulatory obligations animals necessary research recognise aspects research support appropriate use products maximise committed acting ethically providing animals raise ethical concerns including relating benefits minimise risks patients health wellbeing practising good animal animal clinical research use emerging welfare principles applied studies technologies aim address concerns overall responsibility framework sits carried within gsk facilities conducted open approach regularly engaging chief medical officer supported medical external contractors behalf academic scientists regulators policymakers governance boards across business ensure stakeholders consistent operation medical governance rs developed new gsk policy guidance ultimately gsk would like see important benefits clear accountabilities reenforce clear distinction research applied humans without need scientific engagement product promotion animal testing believe achieved foreseeable future goal use animals scientifically necessary use scientifically guide research must understand unmet feasible minimise pain distress medical needs patients focus daily work meeting needs focus patient scientists apply rs principles replacement programme helps us bringing patients reduction refinement biomedical research gsk sites speak directly rd teams replacing animal research methods specific healthcare needs read rd possible programme reducing number animals used still providing information given amount precision refining techniques minimise pain distress maximise animal welfaregsk corporate responsibility report behaviour research practices animal research encourage rs culture gsk regular training performance change number animals used gsk staff involved care use animals raising number animals used lower compared key drivers animal use awareness encouraging best practice recognising two main drivers animal use rd employees made significant advances investment vaccine sales increased implementing rs animal welfare awards period progress rs animal use declined compared faulty genes cause contribute number serious continue see yearonyear decrease since potentially fatal illnesses cystic fibrosis reflecting number factors including changing research forms motor neuron disease valuable method priorities fewer vaccines requiring testing animals understanding potential treatments genetic batch release continued focus rs initiatives disorders involves making small changes responsible animal research conducted contractors behalf animals used within gsk facilities genes rodents scientists model accounts around total animal use animals used contractors behalf gsk human illness examine changes rd investment plus vaccine sales animals used gsk research including experimental medicines may affect development research carried contractors rodents mainly control condition however process also leads rd investment plus vaccine sales two main drivers animal use rats mice nonrodents account figures normalised first year data formation birth animals carry modification number animals used glaxosmithkline data include animal research conducted external therefore suitable research contractors behalf data unavailable less animals use nonhuman gsk scientists developed method sample primates number decreased onehalf species used gsk animal research screen dna sperm mice determine since made voluntary commitment mice carried desired modification means longer perform research great apes male mice likely pass required gene fish selected used breeding led future strategy group programme see rabbit approximately reduction number animals examined approach conduct animal dog bred achieve stable genetically modified line research global basis team drew views nhp team carried shared work stakeholders including welfare organisations ferret peerreviewed scientific publications regulators integrated strategy proposed focusing farm presentations conferences delivering highest quality science least reliance bird animals included building commitment animals used type biomedical development innovative alternatives animal mouse research rodents majority mice detail found published position online research optimising animal studies enhanced rat scientific review finding ways maximise harness guinea pig use research data bolstering external collaborations area strategy endorsed rodents wilson sheardown transgenic res apr approved global implementation nhp refers nonhuman primates farm indicates use pigs goats sheepgsk corporate responsibility report behaviour research practices animal research strategy global governance advocacy around animal principles scientific engagement research responsibility office chief animal welfare veterinary medicine essential research five principles scientific channels provides strict separate departments responsible products meet needs engagement adopted framework engage stakeholder daily care animals accountable delivering patients reflect latest reinforce commitment groups including healthcare objectives identified future strategy group scientific thinking achieve intent actions professionals payers patient also assessed one core principles development medicines scientific engagement advocacy media animal research need research reviewed carried discussion stimulate accelerate demand focus scientific engagement ethical review panel applied worldwide exchange scientific medical gsk products gain favour resulted changes found high level consistency topics information gsk prospective prescribers way work example local committees look review process outside experts stakeholders customers principles ensure strengthened medical agreed six supplementary principles help local ethical helps ensure research gsks values transparency accountability governance review groups apply policies practice include adds scientific understanding integrity respect patient focus scientific engagement activities composition ethical review panels use trained advances care patients underpin intentions actions appropriate ensured competent personnel evaluation alleviation however important scientific engagement governs budget activities resides pain distress legitimate scientific engagement way engage publishing medical function example seen gsk animal research laboratories europe asia science scientific literature change made postpone promotional intent north america aim achieved present science scientific disease awareness activities accreditation association assessment developed new gsk congresses seek gain advice product development accreditation laboratory care aaalac international policy standards reinforce external stakeholders provide product authorisation achieved accreditation facilities hungary clear distinction scientific medical information answer firmly believe scientific france sirtris facility usa aaalac dialogue promotional activity unsolicited questions engagement fundamental gsk accreditation covers animals housed new standards introduced products provide support develop medicines value gsk facilities april called scientific medical education scientific patients strengthening engagement govern engagement policy areas standards part ongoing way engage scientific governs approach commitment continually evaluate activities advisory boards product gains necessary conduct business publications scientific congresses authorisation approval ensures reflect gsks values medical education addition approach scientific engage stakeholders engagement prior product including healthcare professionals authorisation covers congress physicians payers patients sponsorships using digitalgsk corporate responsibility report behaviour research practices clinical research clinical research use variety procedures protect confidentiality working healthcare professionals research participants data ensure conduct clinical research clinical trials healthy volunteers patients enable us individuals identifiable medical data kept securely assess investigational medicines potential protected inappropriate use disclosure read gsk conducts clinical trials working healthcare evaluate medicine approved approach privacy professionals act investigators studies marketing conduct clinical trials accordance policies require clinical trial investigators good clinical practice gcp guidelines developed recognise ongoing treatment clinical trial selected solely qualifications conduct good international conference harmonisation participants medicines end trial quality clinical research history using principles contained world medical association sometimes required continued care patients using gsk products must taken account declaration helsinki ethical principles general responsible funding payments governed contracts compensation medical research involving human subjects medicines trial responsibility reflects fair market value work performed governments providers part national trial protocols reviewed ethics committee healthcare systems however beginning trials services provided payments offered made independent gsk made members diseases conditions continue influence investigators judgement enrolment public medical professionals scientists ethics completion trial must assured maintenance research participant clinical study committee power reject stop clinical trial healthcare system able provide take gifts permitted healthcare professional involved research projects gsk conduct clinical trials countries responsibility continued care patients know outset intend pursue exceptional specific circumstances provision made commitment disclose research payments registration make product available use medicines may funded gsk trial made healthcare professionals institutions country gsksponsored clinical trials conducted read policy clinical trials first annual disclosure made usa ethical standards irrespective take developing world online captures payments phases medicine discovery place require contract research organisation development including clinical trials see us carrying trialrelated activities behalf meet website detail outside usa disclose standards payments healthcare professionals research institutions aggregate basis commencing safety clinical trial participants paramount publication payments made read importance evaluate safety throughout phase clinical trial programme potential clinical trial participants must voluntarily confirm willingness participate informed study benefits risks known informed consent aim provide information potential trial participants nontechnical style lay person understand reviewed updated informed consent form make clearer patientsgsk corporate responsibility report behaviour research practices clinical research training auditing clinical trials addition investigations conducted response public disclosure clinical research suspected irregularities investigator sites cros employees involved gsksponsored clinical research gsk committed public disclosure clinical local operating companies gsk fully investigates receive training good clinical practice gcp research evaluates investigational authorised concerns issues identified takes corrective employees must complete required training medicines irrespective whether results perceived action appropriate corrective preventative undertaking roles relating clinical research positive negative medicines believe actions might include example retraining increased gcprelated training activities fundamental advancing medical science monitoring cases significant persistent non represents successful completion elearning informing prescribers patients scientific findings compliance identified impact module instructorled course relating medicines commitment addition patient safety integrity data severe action legal regulatory requirements disclose relevant risk management compliance framework includes including termination activities reporting data clinical trials safety information independent audit assessment conduct regulators may taken regulatory authorities clinical trials audits assessments cover gsk systems regulatory authorities also performed inspections processes well external contract research disclose results research publicly gsk investigators use conduct clinical organisations investigators conducting clinical accessible clinical study register website launched trials research behalf report audit results quarterly receives average visitors month rd compliance board annually risk gsk completed compas trial clinical otitis well databases registers required laws oversight compliance council audit media pneumonia study argentina assessing regulations clinicaltrialsgov usa risk committee gsks board directors efficacy pneumococcal vaccine synflorix january information available gsk site includes protocol trial subject media coverage regarding summaries ongoing studies summaries conducted clinical quality assurance administrative conduct trial results completed clinical studies read assessments example position disclosure clinical trial information online investigator sites conducting gsksponsored clinical regular monitoring identified trials representing around sites provide administrative errors process obtaining primary data regulatory approval based informed consent small proportion study number results summaries gsk clinical trials gsk processes including process review participants proactively reported national gsk clinical study register regulator immediately put corrective action plan clinical trial imaging data process management human biological samples place trial centres doctors involved number summaries cumulative total time safety participants put risk contract research organisations cros carrying regulator agreed trial could continue planned clinical trials gsks behalf conduct clinical trials high standards gsk local operating companies involved clinical irrespective world run trial activities includes requirement obtain informed consent new drug application nda annual reports participants fundamental principle reviewed prior submission us food drug behaviour continue actively review procedures administration fda provide update ensure best practice minimise risk status study completed progress errors occurring future gsk corporate responsibility report behaviour research practices patient safety changed policy timing patient safety improvements innovation disclosure clinical research medicines previously aimed disclose results summaries trials patient safety always priority evaluate continue improve patient safety systems investigational medicines time first approval benefits risks medicines medical devices safety databases monitoring processes example following termination investigational medicine stages research well new product changed approach disclose results approved sale developed enhancements enable rapid review safety following completion studies rather following medicines potential risks well benefits information observational data sources approval termination medicine although everyone takes medicine worked regulatory agencies observational gsk made commitment seek publication experience side effects important identify medical outcomes partnership omop publicprivate results clinical research evaluates evaluate minimise safety concerns ensure partnership understand best detect safety issues medicines full papers peer reviewed scientific overall benefits medicine outweigh risks established system provides us realtime alerts journals publications provide peerreviewed context product safety assessed clinical trials product sudden changes number adverse event reports interpretation research data putting approved marketing sometimes adverse events received month particular product place systems resources meet commitment possible side effects may detected approval created pharmacovigilance centre excellence product used large numbers patients refine approaches medicine safety also committed disclosing full protocol policies governance framework place help study study published full paper us detect act adverse events dedicated team new capabilities scientific literature interested parties scientists healthcare professionals across world gsk committed providing transparent information see research carried specific role monitor communicate safety health issues patients healthcare providers issues regulatory authorities also work importantly gsks policy prohibits ghost writing regulators example establishing new teams government officials industry partners policymakers journal manuscripts requiring authorship focus clinical effectiveness gsk medicines enhance safety systems medicines vaccines acknowledgements scientific publications assessing benefits risks development consistent requirements international global safety board makes decisions product postapproval period gsk several groups working committee medical journal editors guidelines safety issues remit ensure safety focus advance capabilities internally externally throughout product development review safety goal new team achieve greater integration gsk products market board chaired efforts allow us give better evidence chief medical officer composed senior clinical comparative effectiveness medicines physicians scientists build stronger regulatory files inform physicians regulators payers value medicinesgsk corporate responsibility report behaviour research practices patient safety collaborations patient safety benefitrisk management adverse events reported gsk recorded work government officials industry partners global safety database clinical trial database assess balance benefits risks policy makers enhance safety systems medicines investigated report potential safety concerns particular medicine throughout lifecycle early vaccines two examples many global regulatory authorities regulators countries also development clinical research product collaborations include publish information adverse events internet market available safety information evaluated cofounders international serious adverse documented build detailed benefitrisk profile responding adverse events events consortium isaec nonprofit collaboration product use information develop benefit adverse events affect benefitrisk profile partners including pharmaceutical companies risk management plan identifies ways improve product corrective actions may needed minimise academic institutions regulatory bodies products benefits minimise risks plans reviewed risk include carrying additional clinical working improve patient safety identifying genetic updated regularly clinical development research understand concern modifying variants predict adverse events isaecs initial period product approved marketing prescribing information communications research focused druginduced liver injury collecting reporting safety data physicians healthcare providers druginduced serious skin rashes globally establishing specific methods minimise risk receive information adverse events possible side agreed definitions druginduced liver injury example highlighting warning prescribing effects several sources including patients analysis drugs associated serious skin information products subject limited healthcare professionals regulatory authorities post toxicity published distribution programmes prescription specialist marketing clinical research gsk staff undertake participation critical path institutes mandatory training adverse event reporting doctors certain cases may appropriate stop predictive safety testing consortium independent required immediately report issues relating clinical trial withdraw product market nonprofit organisation brings together scientists safety quality medicines read global specialist committees review approve industry academia share validate expectations code conduct prescribing information medicinal products safety testing methods guidance us ensure updated appropriate food drug administration fda european medicines agency ema several studies sharing new read online ways predict safety issues clinical trials post marketing published shared us clinical trials developing world european regulators cloning technologies stem cell research disclosure clinical trial information care welfare treatment animals role transgenic animals biomedical research aithal gp et al case definition phenotype standardisation u se nonhuman primates nhps discovery druginduced liver injury clinical pharmacology therapeutics p development medicines vaccines papay j et al spontaneous adverse event reports stevens johnson syndrometoxic epidermal necrolysis detecting associations wwwgskcomreportsandpublicationspolicies medications pharmacoepidemiology drug safety article first published online dec gsk corporate responsibility report behaviour supply chain patients consumers rely manufacturing division strong track record finalised agreement us quality compliance current good manufacturing government respect investigation us provide uninterrupted practice cgmp requirements committed process negotiating corporate integrity agreement supply medicines products continuous improvement manufacturing processes cover manufacturing compliance matters last year invested million improving second warning letter issued manufactured highest updating equipment average concerns manufacturing standards worthing facility quality standards inspections regulatory agencies year impacted manufacturing suspended additional manufacturing sites located countries controls implemented production effective responsibly managed supply two us food drug administration fda resumed patients consumers quality distribution system essential us get highquality warning letters cgmp deficiencies since products always priority products right places right time dont year glaxosmithkline formed first concerned peoples health may suffer lives manufacturing issues cidra facility may even risk protect interests patients fully resolved site closed due consumers aim work responsible suppliers declining demand medicines made meet quality social environmental standards gsk human rights supply chain gsk strives conduct business consider human rights issues knowingly use suppliers thirdparty suppliers routine interactions responsible human rights share commitment high critical suppliers environmental infringements identify ethical standards operate health safety audits potential human rights issues make responsible ethical manner new existing critical suppliers recommendations also include questions help us supplier improve performance human rights clauses included identify potential breaches followup supplier contracts covered human rights clauses suppliers significant gaps third party code conduct asked information policies available online include members practices relating limited forced labour pharmaceutical supply chain child exploitation slavery workplace age limits employees initiative psci industry conditions non discrimination discrimination employees collaboration set guiding wages benefits working hours local population principles standards suppliers read human rights statement prevention abuse individuals include human rights online information labour issues psci looking wages benefits working hours clauses included contracts ways improve supplier standards rights workers organise especially emerging markets recognition worker organisationsgsk corporate responsibility report behaviour supply chain supply distribution process supply distribution process making products requires ingredients supply distribution process materials buy suppliers fed interests patients consumers must come first ensuring continuous supply network manufacturing sites countries every stage supply distribution process highquality medicines manufacture nearly gsk products produce planning essential patients planning involves decisions must make approximately four billion packages annually including consumers depend deliver entire lifecycle product helps tablets creams ointments inhalers injections products well us configure location capability capacity liquids people work global success business network internal thirdparty manufacturing sites manufacturing supply gms division also spend around billion order maximise efficiency security supply outsource terms production costs suppliers billion ensuring continuous supply highquality medicines product manufacturing thirdparty manufacturers materials directly required vaccines consumer healthcare products essential provide us finished partfinished product buying manufacture patients consumers depend products responsible manufacturing requires products products spent well success business make made us consistently suppliers high quality countries worldwide buying involves gsk spending around billion suppliers around billion spent distributing products relies working people active ingredients chemical intermediates packaging companies ship customers countries work manufacturing components materials directly required products must stored correctly handled carefully supply division across manufacture products spent throughout distribution points destination making sites countries suppliers countries worldwide depend ensures patients consumers get full benefit make nearly suppliers consistently deliver value low cost products protects reputation provider gsk products produce also produce goods responsible manner highquality effective medicines vaccines consumer billion packages annually support impartiality phases procurement healthcare products cycle standard payment term suppliers supplying products means protecting ship products minimum days receipt invoice customers countries distribution system disruption establish ensuring products stored maintain contingency stock active pharmaceutical distributing correctly handled carefully regional distribution total spend suppliers ingredients finished product important throughout distribution products especially medically critical products destination regularly assess supply chain risks europe appropriate ensure get key raw materials us work protect ingredients alternative suppliers necessary asia pacific distribution system get wrong possible ramifications africamiddle east disruption maintaining health wellbeing customers supplying latin america contingency stocks regularly assessing supply japan chain risksgsk corporate responsibility report behaviour supply chain supplier standards supplier standards higher risk suppliers identified assessed gsk supports suppliers improve standards identify suppliers may require engagement supplier expectations standards ethical monitoring higher risk suppliers identified based work suppliers improve standards conduct labour practices protection human rights critical supply chain risk example ehs management systems interactions gsk pose business fail meet standards audits identified number significant supply employees defined third party code person responsibility gsks relationship interruption risks well risks life safety one conduct code also requires suppliers embed supplier must ensure potential risk indian suppliers multiple ethical standards within supply chains supplier appropriately managed work supply agreements escalated within gsk require new suppliers accept comply procurement colleagues internal audit investigate result restricted supply arrangements principles code business concerns procurement risks integrated gsks supplier provides evidence environment gsk overall risk management compliance oversight process health safety managed responsibly code updated strengthened problems supplier work significant risks effectively managed reflect requirements uk bribery act improve situation possible supplier working address concerns issued guidance employees changes added intractable difficulties end relationship improve processes controls additional clauses antibribery corruption also carried indepth audits two contract templates purchase order terms auditing suppliers critical suppliers one europe one india conditions believe policies processes focusing specific key risks reviewing ensure respect human rights outlined report selecting new critical suppliers governance risk management processes align requirements us california pivotal business conduct audit enabled us build closer productive transparency supply chains act came environment health safety performance risks relationship suppliers agree plans effect beginning systems audit tools also include questions help improvement help mitigate risks us assess potential suppliers performance working suppliers extend approach human rights clauses included supplier contracts critical suppliers new suppliers required meet expectations third party code conduct outlined identify significant gaps suppliers policies procurement teams engage existing suppliers systems performance take one number raise awareness code reinforce ethical courses action recommend use external principles procurement staff procurement consultants support supplier making improvements responsibilities receive training thirdparty management andor may suspend restrict supply significant includes supplier compliance human improvements made cases may stop rights standards ethics training employees also working supplier decide work covers standards supply chain potential new suppliergsk corporate responsibility report behaviour supply chain performance collaborating others industry performance supplier ehs audits pharmaceutical supply chain initiative psci give existing potential suppliers suppliers information need meet industry conducted environment health safety ehs expectations labour ethics environmental audits existing potential suppliers health safety management systems psci around audits assessed suppliers asia americas members developing guidelines tools significant ehs audit findings suppliers europe mechanisms enable shared approach audits occurred mainly emerging markets included asia pilot audits proposed deficiencies fire risk management emergency africa quality audits response capabilities absence fundamental risk total number audits controls process safety inadequate control exposure conduct audit quality standards new hazardous substances inadequate waste management manufacturing material suppliers environmental controls gaps compliance number types supplier audited ehs quality audits performed gsks material supply regulations three five potential new existing potential suppliers chain suppliers provide ingredients form part suppliers audited failed meet products taking coverage quality audits minimum requirements type supplier americas europe asia total manufacturing material suppliers companies primary raw materials audited approved gsk suppliers find gaps risks consider extent intermediates approved providing met certain conditions may take number actions include pharmaceutical ingredients restricting supply significant improvements contract manufacturing worked number key suppliers made using potential new supplier working pharmaceutical develop quality improvement plans designed bring supplier ensuring investment made address formulations standards gsk expects deficiencies always provide findings help consumer healthcare work educate suppliers quality requirements excipients actives suppliers make improvements continued throughout training sessions taking raw materials place nigeria south africa china indonesia pakistan india philippines gsk part rx industry consortium agreed sectorwide standards quality audits product ingredient suppliers mean suppliers used number companies audited rather multiple times results shared purchasing companies quality audits environment health consortium began auditing suppliers behalf manufacturing safety audits current members yearend carried audits material suppliers potential suppliers findings noncriticalgsk corporate responsibility report behaviour supply chain security supply security supply anticounterfeiting gsk trains local staff spot report counterfeit products invest measures find ensuring continuous supply highquality medicines estimated onethird medicines vaccines serial offenders analytical support team uk vaccines consumer healthcare products essential healthcare products parts world may example trialling test uses vapour health depend products well counterfeit counterfeits almost certainly fake toothpaste link counterfeit samples found success business supported quality control testing monitoring around world counterfeit manufacturer later often contain little legitimate active significant threat security supply identified means gsk able provide ingredients needed might include impurities earthquake tsunami japan within evidence scale scope illegal activities colourants microorganisms means many hours mobilised gsk crisis response team hopefully result stiffer penalties patients countries may receiving despite difficulties affecting communications air treatment need worse could taking founding member pharmaceutical security freight road traffic able monitor suppliers substances actually cause harm institute psi gsk works closely wider japan providing materials gsk sites counterfeiting poses threat patient consumer pharmaceutical industry investigate cases worldwide total two materials went stock health well serious business threat gsk counterfeiting well governments supplied one site able ensure pharmaceutical companies international organisations various gsk teams work disruption patients business together investigate suspected incidents counterfeit minimal use anticounterfeiting packaging features gsk products conduct forensic analysis initiate legal holograms security seals complex background action offenders patterns difficult counterfeiters photocopy scan read pilot anticounterfeiting programme conducting using text messaging ampiclox antibiotic nigeria partnering suppliers crisis major fire damaged uk situation became good example equipment transferred factory owned one key strong partnership suppliers alternative factories gsk suppliers march supplier benefit companies sites thirdparty continuity supply gsk manufacturers within six hours start products risk launch fire crisis management team working together able schedules new antiepileptic gsk experts supplier maintain supplies medicines medicine trobalt also set patients minimising disruption jeopardy good products plan put place impact business working relationship resume production quickly supplier potentially disastrous possible products andgsk corporate responsibility report behaviour supply chain supplier diversity supplier diversity work business advocacy organisations gsk anticounterfeiting activity national association veteran business owners small companies owned women people us uk national minority supplier development number belong minority groups often council womens business enterprise national reported cases represented supply chains large companies council identify develop small diverse businesses counterfeit gsk believes small diverse businesses suppliers particularly development number raids significant potential meet procurement needs mentoring initiatives number arrests recognise value bring communities global supplier diversity initiatives outside usa cases included work indian police job creation revenue generation sourcing include sponsorship global link programme raid factory near delhi making counterfeit diverse suppliers benefits gsk helps helps diverse suppliers around world develop version childrens medicine calpol leading two us comply regulations markets usa partnerships local businesses expand arrests raids carried pakistan resulting encourages innovation exposes us new perspectives capabilities access new technology seizure different types counterfeit fresh ideas supplier diversity programme led targeted efforts uk south africa usa support procurement medicines number arrests raids teams worldwide counterfeiting factories china help chinese police concluded longterm investigation usa finding challenge identify small raiding two counterfeiting factories fuyang city diverse businesses fulfil federal size standards guangdong province yongcheng city henan time enabling us reduce costs consolidate province twelve counterfeiters arrested global suppliers spend small diverse suppliers counterfeit medicines value million rmb decreased however plan seized network shanghaibased counterfeiters increase spend small diverse businesses selling products internet also broken beyond counterfeiting problem emerging markets read online usa offender sentenced seven years prison ordered pay gsk read standards compensation found packs third party code conduct weightloss treatment alli sold ebay contained dangerous levels controlled substance sibutramine antibribery corruption programme third uk oneyear sentence fines handed party guidelines pharmaceutical importer raid premises human rights statement including clauses uncovered packs illegally imported seretide supplier contracts placed counterfeit packaging gsk counterfeiting healthcare products wwwgskcomreportsandpublicationspoliciesgsk corporate responsibility report behaviour public policy patient advocacy public policy activity lobbying public policy activities conducted industry association memberships include external affairs teams major regions pharmaceutical industry organisations association support legislative measures business units monitor proposed legislative reforms british pharmaceutical industry abpi european programmes encourage scientific policy developments stakeholder concerns meet federation pharmaceutical industries associations regularly government officials others efpia international federation pharmaceutical innovation balance interests multilateral organisations ngos explain views manufacturers associations ifpma japan business public policy issues also respond directly pharmaceutical manufacturers association jpma gsk asked comment lobbying issues affecting organisation pharmaceutical producers india oppi stakeholders also work whole pharmaceutical consumer healthcare pharmaceutical research manufacturers america patient professional groups industry sometimes conducted trade associations phrma chinas rdbased pharmaceutical association help members gain stronger may also hire lobbying consultants support committee rdpac public policy work voice healthcare consumer industry organisations european brands trade industry associations association aim association european self medication industry aesgp european cosmetics recognise stakeholders concerns gsk member many national regional association colipa union european soft business lobbying aim address international trade industry associations membership drinks associations unesda open approach issues engage groups help support efficiency effectiveness public policy work general industry organisations intellectual property owners association ipo international chamber important lobbying trade industry commerce icc national association manufacturers associations reflects policies values work nam confederation british industry cbi members set policies may attend industry association meetings governments gsks chief executive sir andrew witty currently stakeholders association adopts public policy president european federation pharmaceutical position agree participate industries associations advocacy activity related subject also raise concerns may particular advocacy position directly association management teamgsk corporate responsibility report behaviour public policy patient advocacy public policy activity public policy activity europes healthy ageing initiative european congressional leaders adopt mandated rebates union set pilot publicprivate partnership medicare part may consider similar believe conduct advocacy work active healthy ageing aims increase proposals coming years continue look responsibly make valuable contribution debate average number healthy life years two chief ways trim federal budget usa gsk issues impact business work balance executive steering group partnership industry partners analyse new proposals interest business stakeholders january gsk submitted two proposals action become available continue provide information engaged wide range issues around world support initiative one encouraging greater lawmakers importance maintaining patient included healthcare reform pricing adherence prescriptions among elderly people access innovative pharmaceutical products vaccines intellectual property issues vaccination elderly proposal patent litigation europe discussions continued adherence prescriptions one five actions year particularly challenging public policy proposed introduction single commission agreed pursue implement perspective due healthcare reforms major markets european patent centralised court patent gsk asked lead action austerity measures implemented many litigation gsk supports principle single eu patent beyond proposal supporting comprehensive countries arising economic crisis recognising potential way reducing cost obtaining vaccination programmes elderly people need economic responsibility argued maintaining european patents provided quality discussed approach costcutting measures would achieve judicial process consistently highest order appropriate balance managing costs medicare part usa involved also support concept centralised court incentivising innovation interests patients defending medicare part federal prescription drug disputes european patents resolved eu payers industry insurance programme medicare beneficiaries wide basis timely costeffective manner gsk federal lawmakers proposed pharmaceutical discussing reform project many years examples provide insight approach industry pay mandated rebates medicare part european commission others areas focus way reduce annual budget deficit usa continue involved healthcare reform usa gsk along industry partners phrma wake passage affordable care act opposed proposal would gsk submitted comments number proposed fundamentally altered success medicare part ds regulations healthcare reform implementation competitive marketbased structure supportive acts goal increase access health gsk met federal lawmakers raise awareness insurance million americans success medicare part explain current also support provisions law expand access programme already resulting reduced healthcare preventive services promote development costs example study journal american valuebased care delivery models accountable medical association found improved access care organizations patient centered medical homes adherence medicines resulting part saves believe reforms implemented ways medicare per year hospital nursing home recognise role medicines vaccines costs elderly person previously reducing healthcare costs improving health outcomes lacked comprehensive prescription drug coverage patients reducing prevalence costliness billion per year savings across medicare chronic diseasegsk corporate responsibility report behaviour public policy patient advocacy public policy activity support regulatory cooperation tobacco dependence cessation encouraged oncology drug parity insured cancer patients european union china chinas regulatory eu governments ensure national smoking usa higher outofpocket costs environment pharmaceuticals evolving cessation strategies provide smokers greater support prescribed oral anticancer drugs covered drug increasing cooperation european union motivation stop gsk sells tobacco cessation benefit versus intravenous medicines covered china issues gsk believes stronger products nicorette niquitin provides financial medical benefit disparity lead treatment regulatory environment china aligned support smoke free partnership sfp decisions based dosage form rather international standards protect interests organisation aims promote tobacco control appropriate clinical option patient patients pharmaceutical companies example policy research european national levels thanks talked patient organisations legislators current regulations companies required gsk grant sfp developed smokefree policy importance eliminating cost disparities repeat china clinical trials new vaccines even map europe oral iv oncology medicines five states adopted approved marketing elsewhere oncology parity legislation better oral health europe oral diseases remain delays registration vaccines china major public health challenge europe representing pricing saudi arabia saudi arabian therefore delays chinese patients access potentially annual public health spending estimated government reforming legislation governing pricing lifesaving products vaccines available elsewhere cost eu member states billion year sponsored pharmaceutical products gsk believes supported european commission new platform better oral health europe joint transparent easily understood system pricing efpias cooperation china issues initiative european association dental public needed create stability marketplace help included support workshop increased health association dental education improve access medicinesany new legislation cooperation clinical trials quality control europe raise awareness oral health issues support swift introduction new innovative way forward foster innovation competitiveness link overall health well lobby common products reward innovation treat local trade held euchina highlevel regulatory approach european oral health policy multinational companies equally working meeting devoted pharmaceutical vaccines issues trade associations advocated consultation anticounterfeiting europe continued may proposed changes make sure new advocate paneuropean serialisation system system meets saudi healthcare needs addressing noncommunicable diseases member medicines believe needed reduce long term need sustainable pharmaceutical international federation pharmaceutical manufacturers opportunities counterfeit medicines enter industry also focused specific issues associations helped develop point framework eu supply chain introduced paneuropean system proposals would impose significant price action industry noncommunicable diseases would enable pharmacists across europe check whether discounts patented products mostly produced advance september united nations summit pack already dispensed elsewhere within multinationals generic medicines mostly issue eu therefore help detect counterfeits produced local companies patent reform usa lobbied support faster patient access medicines taiwan america invents act patent reform legislation worked regulatory health authorities shorten became law believe modernisation time takes new medicines get market us patent trademark office uspto necessary example speeding process agreeing create predictable equitable efficient patent system reimbursement prices establish fair reasonable boundaries challenging patents uspto courtsgsk corporate responsibility report behaviour public policy patient advocacy political contributions lobbying political contributions lobbying expenditure usa spent federal lobbying activities includes costs salaries gsk make corporate political contributions benefits employees registered lobby us usa employees choose make personal government use lobbying consultants support political contributions gsk political action lobbying contacts planning activities committee pac facilitates voluntary political research running gsk washington dc government contributions eligible employees accordance affairs office support staff portion trade federal election campaign act association fees associated federal lobbying gsk employees pac contributed also report state lobbying expenses line republicans democrats applicable state laws unaffiliated party candidates running state federal offices contributions policy groups costs associated lobbying eu institutions gsk contributes various groups provide forum range declare policy analysis debate includes think tanks eu commission european parliament number countries certain groups usa voluntary register interest representatives organised sections c c includes running brussels advocacy office us internal revenue code gsk requires salaries external events travel accommodation recipient organisations usa agree refrain consulting costs educational materials figure using gsk funds support oppose federal state takes account proportion employee time local candidates political office spent representing gsks interests order avoid read online double reporting register figure excludes trade association membership fees responsibility declaring lie respective organisations publish positions key issues online including p ublic health access healthcare developing countries pricing reimbursement market access conducting research development antibribery corruption programme ur approach intellectual property counterfeiting healthcare products environmental sustainability wwwgskcomreportsandpublicationspoliciesgsk corporate responsibility report behaviour public policy patient advocacy patient advocacy patient advocacy also set advisory boards usa launched minimum standards working europe include representatives wide range patient groups europe end help ensure patient groups nonprofit organisations founded patient groups also allow us access views engagement patient groups prioritised patients caregivers family members health patient groups subjects clinical trials underscore commitment patientcentric professionals important stakeholders gsk pharmacogenetics information provided patients company example new standards state engage healthcare providers governments ethical issues general manager country must meet minimum media patients promote improved treatment number patient groups year employees services patients also campaign issues engagement designed market products trained work highest ethical affect patients caregivers lives including increasing indeed strict rules never promoting gsk standards patient groups access quality medicines services information medicine patient group never seeking endorsement disease carry research causes medicine patient group aim usa advocacy alliance development center potential treatments specific conditions transparent possible work excellence coordinates engagement funding funding provide publishing information website patient advocacy groups professional associations provide funding patient groups help dayto national regional state levels coordinated standards working patient groups day running costs defined events activities approach particularly important period support also includes educational assistance training gsk employees relevant third parties work significant healthcare reform center staff collaboration disease awareness patient groups must follow guidelines established state advocacy team includes team prevention projects standard operating procedures sops example six fieldbased staff cover states broken limit amount funding provide six regions relationships patient groups help us better patient groups overall funding state relationships understand patient needs illnesses guides plan extend guidelines emerging markets patient groups must never linked promotion rd turn support helps patient opinions asia pacific region future products also provide training employees heard healthcare debate understand requirementsgsk corporate responsibility report behaviour public policy patient advocacy patient advocacy workshops educational support patient advocacy leaders summits european patients academy therapeutic innovation gsk holds regular workshops patient groups patient advocacy leaders summits pals bring feature sessions helping patients adhere patient advocates together discuss health policy issues patientled consortium funded european drugs regimens improve treatment outcomes develop new skills ways expand influence commission trade association efpia working examples sessions include additionally pals strengthen patient advocacy create european patients academy therapeutic workshop patient group representatives organisations educating advocates creating connections innovation eupati educate patient european breast cancer coalition europa donna building network patient advocate organisations representatives among things design independent cancer patients voice manage improve health communities conduct clinical trials drug safety riskbenefit side effects oral cancer drugs metastatic usa implemented new approach pals assessment patient involvement drug development breast cancer provide engagement local gsk industry partner eupati contributing workshop adherence oral cancer treatment level included series regional pals rpals expertise well staff time funding project regimens european patient groups held six states focusing aspects healthcare starts february meeting members lupus europe umbrella reform introduction state health insurance eupati provide educational organisation national lupus selfhelp organisations exchanges also held event patient groups materials six european languages targeting european understand needs patients lupus washington dc exploring role national advocates countries aims released good practice dialogue patients healthcare professionals implementation healthcare reform guidelines patient involvement held five improved leading better treatment outcomes europe held pals meetings bulgaria latvia annual conferences least five regional workshops seminar patient advocates academics germany netherlands switzerland addition leading patient advocates deliver affordable cancer care high completed courses individuals income countries used eupati internet library therapeutic innovation patient groups publish information work patient groups online europe asia pacific emerging markets regions well information support patient groups working globally including details funding received also voluntarily disclose funding support us website detailed information gsk australia canada found websitesgsk corporate responsibility report behaviour human rights gsk committed upholding recognise industry unique role play recognise support role convention efforts improve health worldwide developing safe biological diversity cbd plays providing un universal declaration human effective treatment ailments affect patients framework conservation biological diversity rights oecd guidelines health strive make medicines vaccines protecting rights countries communities products widely available possible running access share benefits arising read multinational enterprises business sustainable way approach cbd use biological core labour standards set materials online put safeguards place ensure human international labour organization rights people taking part clinical research maintaining high standards human rights helps us get ilo signatory un protected include informed consent process best employees supports relationships procedures protect patient privacy communities near sites ensures supplier global compact voluntary global especially careful protect rights children contracts run smoothly provide reliable supply standard human rights labour involved clinical trials read highquality products protects reputation read approach clinical studies human rights statement online environment anticorruption respect promote rights people note guiding principles business human communities near operations efforts rights endorsed united nations human rights believe governments responsibility define improve access healthcare working help society council june believe represent valuable enforce legal framework human rights broadly fulfil right health un declaration contribution debate regarding companies accordance international laws agreements human rights states everyone right operationalise human rights responsibilities though businesses also responsibilities direct standard living adequate health wellbeing appropriate due diligence going forward consider control human rights operations aim family including medical care best respond challenges set principles act responsibly across spheres influence activities improve access healthcare support includes employees suppliers local communities read health society broadly people communities sections earlier reportgsk corporate responsibility report behaviour human rights activities embargoed countries approach human rights stakeholders concerned gsks business activity countries subject trade embargo employment standards cover issues diversity equal opportunities burma myanmar north korea iran sudan employees health safety protect employees human rights read people communities syria share uns belief people denied access medicines regime operating country aim provide medicines vaccines countries third party code conduct requires suppliers contractors business partners meet need wish purchase observing suppliers gsk standards ethical standards human rights environmental health safety ehs sanctions trading controls apply countries audits help us identify potential breaches human rights clauses read supply chain section behaviour many nations longstanding commitment presence predate introduction measures trade embargoes periods government imposed trade embargoes ensured continuity gsk aims good relationships communities around sites operate ways infringe human rights put safeguards place ensure supply subject specific legal restrictions due communities human rights people taking part clinical research protected read demand products research practices section behaviour embargoed countries countries business support committed upholding universal declaration human rights influence human rights beyond operations efforts improve ilo core standards observe local laws society access healthcare support society broadly fulfil right health read health regulations read online publish positions online including human rights statement gsk convention biological diversity wwwgskcomreportsandpublicationspoliciesgsk corporate responsibility report planet contents introduction waste carbon minimising use supply chain materials source growing business operations environmental stewardship protecting natural resources propellants environmental feature understanding need future governance impact products compliance water performance water operations external assurance committed minimising environmental click arrows impact across go section value chain lifecycle products setting ambitious goals reduce carbon footprint water wastegsk corporate responsibility report planet introduction believe possible deliver targets performance progress sustainable business growth performance target note reduced greenhouse gas emissions facilities protecting resources need overall co impact rose slightly due carbon increased production volumes increased impact future safeguarding reduction gsks overall travel inhaler use patients environment carbon footprint across reduced water use waste sent landfill value chain note sites sending zero waste water implementing environmental sustainability developing product carbon footprint approach strategy across entire value chain raw materials reduction water used individual products identify product disposal strategy focuses carbon consumption across note carbon hotspots measures reduce value chain dioxide emissions contribute climate continued pilot takeback scheme used inhalers change water use waste reduction environmental reduction gsks operational usa uk reducing waste greenhouse gas stewardship covers impacts water consumption emissions materials products aim waste recycled waste pet plastic make new ribena carbonneutral value chain reduction waste landfill bottles started deliver strategy operations received rating performance scored revised simple set measures enable reduction total waste disclosure carbon disclosure project assessment us achieve goals many diverse actions generated operations needed underway environmental stewardship first office building certified gold leed need define mass efficiency new environmental rating system along journey transparent pharmaceutical processes published report partners exploring impact performance progress example participate proportion paper packaging climate change health carbon disclosure project cdp assessment sustainable sources note scored disclosure received rating notes performance also achieved carbon trust targets carbon water waste absolute targets vs standard global certification second year mass efficiency paper packaging percentage targets nnual performance available overall carbon footprint table shows results main environmental water consumption reassess footprint across value targets data following pages provided chain detailed data download available online currently assessing baseline paper packaging sgs verifiedgsk corporate responsibility report planet carbon longterm goal entire supply chain operations value chain carbon neutral understanding carbon footprint supply chain reduced emissions coequivalents straightforward use many varied complex facilities includes energy materials make products gain deeper insights production sources main focus within facilities working closely key suppliers carbon energy efficiency activities analysis examined impacts across value trust advisory consultancy develop product carbon seen decrease coequivalent emissions chain see diagram estimated total carbon footprint approach used individual offset increases manufacturing footprint million tonnes coequivalents products identify carbon hotspots measures production volume productionrelated coequivalent largest contributors carbon footprint supply reduce initial results show impacts emissions increased transport emissions chain material inputs million tonnes propellants vary widely product product read increased combined total reduction facilities used inhalers million tonnes transport emissions read continued make progress sustainable operations million tonnes sourcing including engaging ngos help us shape combined heat power chp generation playing made good progress developing plans sourcing approach development network growing role decreasing carbon emissions areas see sustainability advocates procurement organisation installed five chp units bringing total operating units across sites managing impacts value chain materials operations distribution propellants use end life sgs verifiedgsk corporate responsibility report planet carbon chp helped site irvine scotland reduce burning waste biomass fuel horlicks propellants greenhouse gas ghg emissions past three years site makes active ingredient horlicks factories india use coal generate eliminating cfc gases products completed antibiotic augmentin energyintensive process power manufacturing process creates substantially reduced inhaler emissions aims help secure energy supplies renewable approximately tonnes coequivalent million tonnes coequivalents less sources installing wind power first turbine emissions year approximately total five million tonnes today needs done operating early two follow subject gsks operations replacement propellant still powerful planning approvals together deliver annual sites began trials switch burning greenhouse gas times potent co savings tonnes coequivalents also coal exclusively blending waste biomass increasingly supply dry powder inhalers approved million project convert waste heat use propellant patients children find renewable resource tested number options plant singapore estimated annual savings difficult use continue improve standard rice husk pellets made waste wood tonnes coequivalents sawdust grain straw cotton straw ground nut propellantcontaining inhalers saving energy also high priority office shells trials prove successful ghg emissions propellants increased buildings vaccine site saintefoy quebec plan blend waste biomass three sites primarily due increased sales became first office building certified gold avoiding tonnes emissions year currently investigating improvements including leed environmental rating system new longer term aim waste biomass steam reducing amount propellant needed inhaler pharmaceuticals headquarters building philadelphia generation investment combined heat power trialling takeback schemes also planned meet even higher environmental criteria technology generate electricity avoid propellant releases read overleaf central fund available help develop specific using waste biomass could also contribute local renewable energy energy reduction projects economy creating market waste previously past four years supported projects limited value example proposed pellet saved approximately tonnes co supplier works microentrepreneur scheme equivalents details energy carbon reduction produces incomes local people performance found data download available online carbon disclosure project website reduction inhaler emissions reduced million tonnes coequivalents less five million tonnes today sgs verifiedgsk corporate responsibility report planet feature understanding impact products analysed carbon footprint across value chain estimated total footprint million tonnes co highlighted main contributors emissions supply chain propellant release use inhaler products building understanding need know impacts individual products sgs verifiedgsk corporate responsibility report planet feature understanding impact products developing product carbon footprint approach taking back used inhalers ventolin carbon footprint initial results show vary widely collecting used inhalers avoids waste well greenhouse product product demonstrated contrast gas emissions extended us trial carbon footprints propellantbased inhaler takeback scheme uk work close ventolin inhaler advair diskus dry powder inhalers pharmacists encourage patients return empty carbon footprint respiratory products inhalers collect new one pharmacist sends inhalers gsks recycling partner carbon footprint ventolin showed need separates plastics remanufacturing captures focus reducing release propellant hfa remaining aerosol propellant trial began atmosphere responsible usa pharmacies five cities materials footprint kg coequivalent per device operations exploring range options including reducing uk extended initial trial co packaging amount propellant needed capturing propellant operative supermarket chain pharmacies transport lost manufacturing recycling used devices sixmonth trial estimated purchased inhalers propellant use investigating alternative propellants returned saving propellant potent analysis advair diskus dry powder inhalers greenhouse gas avoided equivalent tonnes advair diskus carbon footprint footprint showed need focus plastics co emissions plan expand programme used make device energy used impact product use operations together account also need understand better environmental product footprint device kg coequivalent impacts products used patients per device shortterm improvement priorities consumers commissioned study focusing options recycle plastics device usephase carbon footprint top products improving energy efficiency operations based estimate usephase emissions one million metric tonnes coequivalent materials excluding impact propellants horlicks operations toothpaste products packaging transport learned emissions product use dependent type product used example prescription medicine largest use phase impact derives paper bag labels attached medicines dispensed pharmacies sgs verifiedgsk corporate responsibility report planet water waste water water operations recycling waste understanding impact business value chain continue sitelevel action improve water use another innovation led waste pet water complex unlike carbon emissions whose reduction see plastic used make bottles ribena previously impacts global water use local global developed water kaizen rapid improvement process waste contractors disposed approximately tonnes impacts needs take account users identify efficient ways use water piloted pet packaging trays used deliver components watershed well seasonality water quality approach worthing maidenhead sites sites ware uk evreux france southeast england identified potential savings material recycled create new ribena bottles gsk active un ceo water mandate many opportunities already saving approximately tonnes cosponsors work develop disclosure guidelines implemented without significant investment coequivalent emissions year guidelines help companies measure examples include fitting aerators taps decommissioning communicate performance effectively hope redundant equipment optimising service water flows ultimately lead water footprint approach similar fitting trigger guns water hoses sites greenhouse gas protocol investigating opportunities identified kaizen performing highlevel analysis across entire process whether high grade waste water one value chain quantify overall water consumption part plant could used elsewhere instead using identify areas risk concern help additional potable water us understand water impacts better identify waste opportunities reduce overall impact initial results suggest greatest contribution water continued make progress reducing impact footprint come use water associated waste total waste hazardous non around raw materials supply chain hazardous fell volumes landfill see also work reduce spread waterborne total sites send zero waste diseases landfill read innovations drive waste many ways example employees xochimilco mexico found way use panelling refrigerated vaccines shipping packaging insulation material construction industry reusing materials avoiding tonnes waste year previously paid send landfill sgs verifiedgsk corporate responsibility report planet waste examples reducing packaging waste driving sustainability external engagement include converting glass plastic bottles horlicks reducing packaging material consumer healthcare continue collaboration gsksingapore pharmaceutical industry copublished products converting blister packs film partnership green sustainable manufacturing key green engineering research areas metrics wrapping nasal spray flixotide estimate programme gsk proposes industry green chemistry measures avoid tonnes co problems sustainability study academic published report accenture equivalents year community prepares research proposals solve university oxfords smith school enterprise problems two rounds proposals awarded revised green packaging guide help environment exploring impact climate change first symposium held designers avoid waste choose sustainable health believe important area awarded another grants singaporean researchers option guide includes sustainability assessment tools little understood research suggested different areas sustainable manufacturing amounting covering energy water use well carbon may benefits temperature changes million footprint packaging materials transport carbon smaller malarial zones parts africa tracker collects data monitor progress rd also worked industry partners overall impact negative climate change could create million sustainable chemistry partnership threaten lives wellbeing billions people minimising use materials source academia european innovative extreme weather directly increase disease continue work increasing efficiency medicines initiative start work death indirectly result regions use materials new pharmaceutical products gsk also part american chemical society struggling sufficient food clean water sanitation average mass efficiency new primary processes green chemistry institute pharmaceutical roundtable worlds poorest people likely affected transferred manufacturing collaborate pharmaceutical research starting point welcome compared target see companies green chemistry engineering opportunity work others develop better believe increase mass efficiency understanding pharmaceutical industry products transferred manufacturing needs respond measures solvent recovery grants created new rd group working second generation product development improve sustainability profile rd manufacturing portfolio projects product lifecycle singaporean creation sustainable found online research areas org process res dev researchers areas chemistry partnership pp metrics org process res dev sustainable manufacturing imi pp report cimate change health framing issue available publications section website sgs verifiedgsk corporate responsibility report planet stewardship governance environmental stewardship environmental governance ceo ehs sustainability awards key tool engaging employees refreshed awards main themes environmental strategy made progress internal governance reflect new strategies aspirations particular carbon water waste also work broad front environmental sustainability internal recognised projects showed demonstrable benefits environmental issues including eliminating use external engagement business strategic areas year received materials concern materials concern responsibility environmental sustainability rests applications chemicals scientific evidence shows probable corporate executive team cet formally environmental sustainability category entries came serious longterm effects humans environment reviews performance year read countries areas carbon water existing potential future corporate responsibility committee also reviews waste general environmental sustainability legislation may restrict use used progress examples awards include programmes energy total tonnes materials development reduction operations improved manufacturing compared tonnes new sustainability steering team met quarterly route new product water reduction initiatives refrigerants cfcs ozone depleting consists senior leaders across one site australia one uk read substances still use sites missed business bring commercial perspective winners ehs categories environmental debates engage local operating target eliminate cfc use however companies issues team responsible external stakeholder panel provided advice reduced mass cfcs used compared shaping environmental strategy integrated environmental sustainability environment mainly due cfc replacement continue business strategy relevant health safety matters met pursue stretching integrate environmental longer meet current form currently restated policy pharmaceuticals sustainability specific business unit goals reviewing approach aiming achieve deeper environment reflect recent scientific growing environmental sustainability practitioner engagement diverse global group advances current practices position remains base helping every employee get involved stakeholders line strategy working across none compounds would expected cause creation network site champions value chain human health environmental impacts environmental sustainability key part continue build deeper scientific understanding environment health safety sustainability ehss issues order address concerns evaluating policy cet approved covers amount pharmaceuticals effluent fundamentals approach risk management manufacturing facilities also support voluntary ambition sustainability commitment responsible programmes dealing safe disposal transparency unused medicines source pharmaceuticals environment sgs verifiedgsk corporate responsibility report planet compliance remain vigilant stay full internal audit compliance environmental audit operations contract manufacturers key suppliers based assessment systems managing laws regulations significant risks impacts compliance legislation performance environment health safety incurred two environmental fines sustainability ehss standards largest rm malaysian ringgit members ehss audit team certified iso approximately kuala lumpur insufficient lead auditors part gsk audit space store scheduled waste prior collected assurance function provides independent audit destruction assurance capability separate management organisation function uses riskbased audit process fine singaporean dollars approximately one sites singapore follows professional practices framework read online potential mosquito breeding canvas sheets left need audit determined modelling key outdoors collected rain water risk indicators trends previous audit findings publish positions online including events followed corrective actions ehss audit strategy prompted audits climate change sites around world included review satisfied requirements impact climate change health environmental management systems addition gsk advised may responsible party team carried theme audit management g enetically modified microorganisms ehs approximately environmental remediation sites hazardous waste across number rd facilities nanomaterials appear us national priority list created hazardous chemical management general performance relating management comprehensive environmental response compensation environmental risks found well managed gsk eu reach regulation liability act superfund gsk convention biological diversity read ehs audits key suppliers supply instances gsks involvement related waste chain section pharmaceuticals environment disposal sites gsk one several responsible parties gsks potential liability varies greatly site ozone depletion metereddose inhalers asthma site gsk routinely accrues funds ensure zone depleting substances plant equipment meet obligations wwwgskcomreportsandpublicationspolicies sgs verifiedgsk corporate responsibility report planet performance made progress carbon performance data summary environmental sustainability strategy co impact operations fell mainly driven note change working towards longterm aim investment projects supported climate change carbon thousand tonnes coequivalents per annum programme also closed number facilities carbon neutral value chain balanced acquisitions growth carbon footprint note overall impact operations transport inhaler climate change impacts use rose slightly due increased production volumes raw materials note increased impact travel inhaler use patients operations operational energy detailed information performance sources found data download available online transport product transport climate change impact operations transport employee air travel inhaler use sales force vehicles million tonnes co equivalents total inhaler use patients target water million cubic metres water use operations waste thousand tonnes use inhalers patients operations energy total operational waste generated travel transport total operational waste landfill sources sources include waste treatmentrelated releases production nonhazardous waste generated releases inhaler production losses refrigerant losses travel transport co coequivalent exclude methane emissions hazardous waste generated notes values restated previous report estimated data december included actual data available time report publication reassess carbon footprint accross value chain annual performance available sgs verifiedgsk corporate responsibility report planet performance water waste destination waste net water consumption fallen due range total waste generated fell slightly driven non water saving recycled water use initiatives across hazardous waste reduction achieved waste reusedrecycled business well site closures reduction reduction projects changes production incineration offset business growth particularly made big progress zero landfill programme energy recovery consumer healthcare manufacturing vaccines sites rolled across business majority waste incineration expansion detailed information found reused recycled onsite followed incineration energy recovery data download available online recycled waste solvents recovered onsite landfill detailed information found data download available online net water consumption operations total waste generated mass efficiency mass efficiency million cubic metres million kilograms total target target hazardous nonhazardous excludes nonroutine waste construction demolition stage stage stage stage stage range average waste landfill chart shows average range mass efficiency process million kilograms development stage pipeline processes transferred rd manufacturing period average mass efficiency target mass efficiency primary processes transferred averaged stage refers transferred manufacturing weighted average sgs verifiedgsk corporate responsibility report planet external assurance basis reporting short form external assurance opinion external assurance assurance statement basis methodology described verification work performed satisfied data energy co emissions data collected collection reporting processes place robust pharmaceuticals consumer healthcare sgs united kingdom ltds short form report manufacturing sites vaccines sites pharmaceuticals environment health safety data environmental health safety data contained glaxosmithkline corporate responsibility report within gsk corporate responsibility report consumer healthcare rd sites uk headquarters reliable provides fair balanced representation building offices distribution centres water sgs united kingdom ltd commissioned gsks environmental health safety activities nonhazardous waste data collected glaxosmithkline gsk conduct independent assurance team opinion report manufacturing vaccines operations rd major assurance environmental health safety data used reporting organisations stakeholders office locations based materiality assessment corporate responsibility cr report collect hazardous waste wastewater data full assurance statement available online scope assurance based sgs sustainability offices sites manufacture consumer healthcare report assurance methodology included signed nutritional products volatile organic compound environmental data contained planet section behalf sgs united kingdom ltd vocs reported sites manufacture report health safety data contained jan saunders pharmaceuticals contain rd pilot plants use people communities section report systems services certification greenhouse gas protocol calculations detailed data table sgs logo found united kingdom rd february co emissions energy use propellants relevant gsk cr report highlight wwwsgscom refrigerants use co country factors electricity data included assurance scope published international energy agency gsk response assurance scope assurance selected based upon sixth year sgs reviewed data pleased sgss findings good practice material issues identified gsk include environment section corporate responsibility recognition robust data collection analysis environment health safety key performance report independent view processes reporting committed continue improving indicators kpis subject corporate level improvement valuable adopted suggestions ultimate goal continued provision accurate data targets assurance included interview document years improving processes public website data corporate reviews gsk facilities london uk irvine uk sites selected review gsk slough uk singapore poznan poland research responsibility report used sites improve management environmental health safety businesses site visits special focus triangle park usa biopharm usa programmes continue working sites top contributors environmental sites improve data submission including providing emissions previous year sites implemented comments explanation trends complete innovative ehs projects relatively new sites timely fashion previously visited sgs data verification sites difficulty submitting data timely manner responses specific areas sgs full assurance statement found online sgs verifiedgsk corporate responsibility report governance management governance management boardlevel corporate committee members sir christopher principles gent chair dr stephanie burns james murdoch responsibility committee dr daniel podolsky going forward james murdoch cr principles underpinned values nonexecutive directors provides decided step board years agm identify key responsibility issues provide offering reelection guidance standards gsk committed highlevel guidance approach cr committee review progress meeting ceo members corporate executive team corporate responsibility cr commitments show cet accountable responsible management reviews policies progress business participate cr committee meetings principles maps one four key themes see important responsible committee meets three times year receiving reports sustainable business growth member cet senior managers review health ensure progress meeting cr principles committee reports findings board access medicines read cr committee report research innovation governance section annual report online augment gsks engagement stakeholder opinion people communities march sophia tickell appointed employment practices independent external adviser committee community investment sophia cofounder director meteos directs pharma futures series aims align better societal shareholder value also behaviour sits expert review committee access standards ethical conduct medicines foundation member european products customers healthcare innovation leadership network sophia attended meetings committee provided leadership advocacy independent advice guidance corporate human rights responsibility matters chairman ceo engagement stakeholders mid avoid conflict interest new role due take sophia decided planet retire adviser committee caring environment detail principles available onlinegsk corporate responsibility report governance management approach cr covers diverse range issues audit assurance external assurance believe managed assess many aspects responsibility performance environment health safety reporting within business functions internal external assurance processes externally assured sgs independent external assurer audit assurance department responsibility relevant subject experts work assurance process includes verification key independently assessing sample basis process environment health safety data site visits controls place comply laws regulations telephone calls ehs professionals review crossfunctional team made company standards across gsk audits focused systems processes collecting collating analysing representatives key business areas oversees key business risks areas gsk interpreting data read assurance statement development implementation communication function responsibility independently assessing policies including responsibility elements across adequacy effectiveness management gsk members team senior managers previously assured one section report significant risk areas reporting outcomes audit direct access corporate executive team every year process reviewing risk committee line agreed assurance plan small central cr team coordinates policy approach assurance sections development reporting specifically relating cr issues identified audit team recommend cr report well communicating responsible investors improvements gsk managers develop action plans risk management stakeholders address causes noncompliance address gaps internal controls department tracks plans risk oversight compliance council rocc completion reports results senior coordinates management significant business management audit risk committee risks oversees internal controls ensure compliance reviewing key business issues antibribery corruption abac programme applicable laws regulations gsk policies strategic challenges builds values standards form nonfinancial reputational risks included recently introduced future strategy groups comprehensive practical approach compliance core risk management processes review approach key business issues complex risk area programme overseen significant risks including nonfinancial risks address strategic challenges led abac team provide advisory support risk management processes described ceos office providing valuable opportunities high routine audits risk annual report potential employees work closely corporate supplement traditional audit programme strategic executive team groups work bring together business growth achieved risk evaluations sres conducted partnership senior managers experts around business acquisition due diligence processes place business evaluate areas gsks risk appetite designed allow innovative thinking designed identify risks posed mitigation strategy unclear undefined based development new approaches several fsgs new business acquisitions including ethical social emerging nature risk risk maturity convened included focus areas environmental risks level gsks response approach malaria access healthcare animal research read approach read assurance internal audit risk progress areas health management governance section research practices sections earlier report annual reportgsk corporate responsibility report governance management value corporate responsibility value corporate responsibility responsible business benefits gsk facilitates greater access markets ability increasing access making products societies operate helps us operate efficiently influence healthcare policy improved accessible affordable gain trust stakeholders create products relationships regulators healthcare payers investing people communities patients healthcare payers really need working governments increase access operate foster right conditions growth business resolve healthcare challenges particularly important ensuring ethical standards research development operating responsibly fully integrating principles helps us anticipate prepare legislative changes sales marketing business strategies longer term remain competitive environmental impact particularly relating supports licence operate ability helps maintain support intellectual property climate change improve peoples lives products system finding innovative ways increase access medicines number factors influence assessment builds trust gsk products including business strategy risk management reduces costs increased environmental enhances ability attract retain motivate processes stakeholder interest including investor efficiency efficient use resources talented people increasingly important fewer feedback changes business operations young people major markets choose science consider following responsibility issues example types product produce based careers material gsk locations operate existing proposed legislation public opinion supports constructive engagement stakeholders contribution make health wellbeing helps us prevent avoidable conflict research development manufacture identify innovative approaches benefit gsk sale medicines vaccines consumer wider society healthcare products annual report read business strategy performance well find f lie el b loe ntt ge er r detail corporate governance risk management annual report shareholders annual report onlinegsk corporate responsibility report governance management stakeholder engagement stakeholder engagement dialogue stakeholder examples engage enables us keep touch healthcare professionals hcps sales representative meetings views opinions societies interactions clinical studies conferences operate helps us identify engagement professional organisations important issues shape patients meetings gsk scientists patients responses interest focus patient programme shareholders wider society work patient advocacy groups market research understand patient needs regular engagement means better informed governments regulators public policy work emerging current issues changing expectations provides opportunity voice approach advocacy key issues access healthcare responsibility issues obtain important feedback build investors meetings investors participation key sustainability indexes trust discussion takes place normal course business provide training help managers participation carbon disclosure project markets communicate local stakeholders employees regular employee surveys approach responsible business transparency ways engage stakeholders consultation employee representatives changes business outlined throughout report local communities interactions site level range issues community investment programmes multilateral agencies engagement access healthcare public health initiatives nongovernmental organisations engagement issues relating access medicines community investment public policy animal welfare scientific community participation academic collaborations participation scientific debates suppliers global regional supplier review meetings meetings diverse suppliers peer companies pharmaceutical industry organisation meetings joint projects pharmaceutical supply chain initiativegsk corporate responsibility report governance management performance gsk receives recognition awards gsk ranked top access medicine index second time june across areas business index ranking reviewed assessed rdbased pharmaceutical companies seven generics companies performance seven criteria provide summary management influence rd pricing patenting capability philanthropy performance key investor focused gsk ranked highest six seven categories indexes awards gsk continued member dow jones sustainability index covers top sustainable companies sector gsk awarded bronze class distinction survey published gsk included ftsegood index benchmarks companies corporate responsibility parameters including environmental sustainability stakeholder relationships human rights supply chain labour standards business ethics gsk also rated top healthcare sector new ftsegood esg rating scoring maximum assessment scores companies approach performance based publicly available information carbon disclosure projects cdp leadership index ranked gsk th global companies score disclosure rating performance thomson reuters extel sustainability sri survey gsk leading quoted company ir sustainability investors award based votes european fund managers investment banksgsk corporate responsibility report front cover left right photo credits early stage research new biopharmaceuticals takes place large p chairman george brooks rd centre stevenage uk people worldwide work p ceo tom whipps rd search new medicines vaccines consumer healthcare p health chris martin left tom whipps right products george brooks p focus patient george brook p approach malaria tom whipps mother child wait outside malaria clinic tanzania p using mobile phones tackle counterfeiting nigeria tom whipps children seven countries across subsaharan africa taking part p approach neglected tropical diseases ntds marcus perkins ongoing largescale trial evaluate malaria vaccine candidate rtss p measuring impact phase programme chris martin tom whipps p treatment children hivaids chris martin p vijana tunaweza newala jennifer mcclearysillsicrw gsk official laboratory services provider london p people communities david tett left george brooks right olympic paralympic games school outreach programme p responding japanese earthquake ap photothe yomiuri shimbun scientists sport aims inspire young people science masataka morita demonstrating role science plays games david tett p b ringing science london olympic paralympic games david tett around carbon footprint comes propellants released p impact awards stamp productions use inhaler products takeback scheme trialled p behaviour tom whipps left george brooks right us uk recycles returned empty inhalers plastics p c hanging way incentivise sales teams usa sean locke manufacturing propellant nonmedical use ian enness getty images back cover p planet thampapon otavornrf left impress photography right visual inspection vials zhangjiang site china quality p burning waste biomass fuel horlicks thampapon otavornrf p understanding impact products ian enness heart activities support discovery supply p understanding impact products impress photography distribution products patients consumers tom whipps p recycling waste george brooks man lymphatic filariasis lf also known elephantiasis cares legs limit effects disabling disease gsk donates albendazole treatment world health organization led effort eliminate lf marcus perkins red cross doctor helps victim japanese disaster gsk donated products worth million million cash japanese red cross gsk japan employee volunteers delivered food blankets aid affected areas ap photothe yomiuri shimbun masataka morita gsks phase programme run partnership ngos works improve water quality well educate communities importance handwashing reducing spread diarrhoearelated diseases gettyclaudia dewald printed amadeus offset recycled paper full fsc certification pulps used made deinked postconsumer waste elemental chlorine free ecf manufacturing mill holds iso eu ecolabel certificates environmental management mill zero landfill extremely low carbon emissions leading wwf approve papers environmentally sustainable uncoated recycled paperwwwgskcom download pdfs reports website annual report corporate responsibility report head office registered office glaxosmithkline plc great west road brentford middlesex tw gs united kingdom tel registered number wwwgskcom